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Abstract
Intrauterine growth restriction (IUGR) affects between 5-10% of pregnancies carrying with it an 
increased risk of mortality and morbidity. Several serum analytes have been studied in the hope of 
finding a relevant marker linked to IUGR, but none of them have proven to be sufficiently accurate 
to be used in routine clinical practice as a single predictive marker. 
IUGR is likely to be caused by both genetic and environmental factors. Studies in rodents have 
identified imprinted genes as some of the major genetic modulators of intrauterine growth. In 
addition, misregulation of imprinted gene dosage in humans is associated with paediatric growth 
disorders.  
One such imprinted gene is Delta-like homologue 1 (DLK1). DLK1 is expressed predominantly from 
the paternally inherited chromosome, while the maternally inherited copy remains silent. Genetic 
aberrations affecting this imprinted gene cluster, as see in both humans and mouse models, result in 
distinct phenotypes affecting growth.  
A small cohort of participants was recruited from the Royal London Hospital, Fetal Medicine Unit for 
this study. Maternal serum DLK1 levels were measured in this preliminary cohort. DLK1 serum levels 
rose during gestation with levels falling after delivery. Furthermore, DLK1 was found to be predictive 
of birth weight and has a positive correlation with fetal growth parameters. 
This analysis was extended to a new cohort previously recruited at the Kuopio University Hospital, 
Finland. DLK1 serum levels were seen to be significantly lower in IUGR pregnancies when compared 
to normal pregnancies.  
Using immunohistochemistry methods I was able to detect robust expression of DLK1 in the fetal 
endothelium and trophoblast cells. Histology studies further identified the presence of 
multinucleated trophoblastic giant cells, a sign of maternal vascular malperfusion, as a finding in 
pregnancies associated with low DLK1 levels. 
These findings allow a better understanding of DLK1. Further investigations are warranted to enable 
elucidation of a mode of action for this protein. 
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Chapter 1: Introduction  
1.1 Mechanism of Fetal growth  
Fetal growth is a complex process regulated by fetal, maternal and placental factors. The drive for 
fetal growth is under the control of the fetal genome, which exerts a significant demand for 
maternal nutrients through the placenta. The right balance needs to be achieved between this fetal 
demand and maternal nutrient requirements; in order to avoid pregnancy related complications, 
which can have long standing effects1. The placenta plays an important role in maintaining this 
balance by adapting to fetal signals of nutrient demand, in addition to maternal signals of nutrient 
availability, thereby allowing for appropriate allocation of nutrients2.  
1.1.1 Factors regulating fetal growth 
A functioning placenta is paramount for fetal growth. Several factors influence transport across the 
placenta including utero-placental and umbilical blood flows, the area available for exchange, 
placental metabolism and the expression of specific transporter proteins in the placental barrier. 
The transfer of highly permeable molecules such as oxygen and carbon dioxide is especially 
influenced by reduced blood flow3. For other substrates, the placenta possesses both passive and 
active transport mechanisms. Endocrine hormones, which can be secreted by the fetus, the 
placenta, or be of a maternal source also regulate fetal growth. In addition gene regulation and 
expression in both the placenta and fetus can influence the process of development in utero. 
1.1.1.1 Nutrient transporters 
Fetal growth is largely determined by nutrient supply, which is mainly dependent upon placental 
nutrient transport. In human pregnancies complicated by either IUGR or fetal overgrowth, placental 
nutrient transporters are found to be specifically regulated suggesting an important role for nutrient 
transfer in fetal growth 4–6. Glucose is a primary substrate for fetal growth and is transported across 
the placenta via GLUT1 (glucose transporter 1) found in both the microvillus and basal membranes 
of the syncytiotrophoblast (ST) layer. GLUT1 is more abundant on the microvillus membrane (MVM), 
which is maternal facing (section 1.2) when compared to the fetal facing basal membrane (BM). This 
allows for transfer of Glucose by facilitated diffusion. GLUT1 expression increases over the latter half 
of gestation concurrent with an increased rate of growth in the third trimester4. IGF1 has recently 
been shown to stimulate glucose transport capacity by increasing the translocation of GLUT1 to the 
trophoblast plasma membrane7. Net glucose transfer is therefore highly dependent on maternal-
fetal concentration gradients8 .  Other nutrients such as calcium are transported by primary active 
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transport9. A number of nutrients are transported across the placenta by secondary active transport, 
utilising energy provided by ion gradients9. Changes in energy availability or ion gradients can 
consequently influence net transfer of substrates transported by active mechanisms. 
The primary barrier limiting nutrient transfer across the human placenta is the ST (Figure 4). The ST 
plasma membranes express numerous nutrient transporters, which may be regulated by fetal, 
maternal and placental signals. Most nutrient transporters are more abundant on the MVM 
compared to BM thereby favouring transport of nutrients in the fetal-maternal direction10. Gene 
expression changes in placental nutrient transporter systems have been seen in pathology such as 
IUGR, pre-eclampsia, chronic hypoxia and diabetes11. This highlights the importance of the nutrient 
transporters in maintaining a normal pregnancy. 
1.1.1.2 Placental vasculature 
The importance of the role played by the placental vasculature in fetal growth can be appreciated in 
the impaired uterine and umbilical artery blood flows seen in IUGR as described in section 1.1.5.  The 
development of new capillaries from pre-existing ones (angiogenesis) requires a well-controlled 
balance between pro-angiogenic and anti-angiogenic factors. The main pro-angiogenic factors are: 
vascular endothelial growth factor A (VEGFA), which is induced by the hypoxia-inducible factor 1 
(HIF1), placental growth factor (PlGF), which is activated directly by oxygen concentrations; and 
angiopoietins ANG1 and ANG211,12. The main anti-angiogenic factors are the soluble, truncated form 
of the Flt1 receptor (sFlt1) and the soluble endoglin (sEng), a truncated form of endoglin (CD105)13. 
Further evidence for the role played by angiogenic factors in placentation is seen in pathology. 
Altered concentrations of VEGFA and its receptors have been documented in human placental fetal 
capillaries from pregnancies complicated by type 1 and type 2 diabetes 14. In addition, placentas 
from women with type 1 and type 2 diabetes have increased fetal capillary volume and length 
compared with controls15. Furthermore, increased fetal capillary volume has been documented in 
human placentas in cases of exposure to chronic hypobaric hypoxia at high altitudes, as well as in 
the context of maternal iron-deficient anaemia16,17. Hypoxia and anaemia have also been shown to 
reduce the thickness of the interhaemal barrier16,17. Factors affecting perfusion and nutrient 
exchange will inevitably influence fetal growth. The process of angiogenesis, including the intricate 
control from various factors working in synchrony, is another example of the placenta adapting in 
response to the intrauterine milieu.  Aspects that interfere with the balance between pro and anti 
angiogenic factors will impact placental function and therefore the trajectory of fetal growth. 
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1.1.1.3 Endocrine control of fetal growth 
As we have seen from the descriptions above, the regulation of fetal growth is complex and 
multifactorial. We have seen how fetal growth can be influenced by nutrient transport and placental 
vasculature. In addition, fetal growth is also under endocrine control. The main hormonal drivers of 
intrauterine growth are insulin, insulin-like growth factors (IGF) and thyroid hormones18. Hormones 
can act on fetal growth directly (via genes) and indirectly through changes in placental growth, fetal 
metabolism or production of growth factors and other hormones by the feto-placental tissues. The 
source of these hormones could be: from the endocrine glands of the fetus (fetal pancreas, thyroid, 
pituitary and adrenal glands); from the uteroplacental tissues (mainly the ST); from the mother by 
transplacental diffusion; and from circulating precursor molecules by metabolism in the fetal or 
placental tissues.  
 
Insulin controls cell number as it has direct mitogenic effects on cellular development. It leads to 
glucose uptake and consumption by body tissues and decreases protein breakdown. Insulin also 
stimulates production of IGF-I while fetal insulin specifically acts as a signal of nutrient availability for 
growth18. Insulin concentration in utero rises between early and mid gestation, thereafter remaining 
stable until term. The insulin – like growth factor (IGF) system is the main established endocrine 
regulator of fetal growth 19. IGF-I is synthesised in utero with the presence of IGF-I mRNA noted from 
as early as 12-14 weeks gestation in humans20. There is a progressive increase in IGF-I and IGF-II 
during gestation. IGF-I is positively regulated by glucose supply to the fetus. Furthermore, fetal 
plasma IGFs are derived from a range of feto-placental tissues throughout gestation21. IGF-I has 
mitogenic properties resulting in induction of somatic cell growth and proliferation and has further 
function in regulating transport of glucose and amino acids cross the placenta22. Thyroid hormones 
present in the fetal circulation are mainly derived from the fetus but can also be of maternal or 
placental origin23.Hypothyroxinaemia in the fetus leads to decreased oxygen consumption and 
oxidation of glucose thereby resulting in decreased fetal energy supply for growth.  
 
Growth hormone is the main regulator of postnatal growth but doesn’t appear to affect intrauterine 
growth24,25. Other hormones that indirectly influence fetal growth mainly through their effect on 
implantation and placentation include oestrogen (oestradiol), progesterone, human placental 
lactogen (HPL), Human placental growth hormone (HPGH), leptin, adiponectin and resistin26.  Leptin 
in particular has been shown to stimulate system A amino acid activity27. Amino acids are an 
important nutrient for fetal growth and development. Placental system A amino acid transporter 
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activity is significantly lower in pregnancies complicated by IUGR28,29. Circulating leptin levels during 
pregnancy are elevated 2 to 3 fold above that observed in non-pregnant women and in addition 
leptin receptors are present in the placenta30. These suggest an important role for leptin in fetal 
growth. We can see that fetal growth is controlled by a number of closely related factors, some of 
which are dependent on each other. It is important for us to understand the events that influence 
the functioning of these factors. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Hormonal influence of fetal growth  
IGF2 and Insulin both have anabolic actions on fetal growth leading to fetal tissue accretion. Thyroid hormones 
influence growth, metabolism and differentiation of fetal tissue. These actions in combination lead to overall 
fetal growth. * Thyroid hormones may regulate leptin gene expression. ** Insulin mainly acts directly but has 
some indirect actions via the IFG receptors.  
 
1.1.1.4 Clinical Presentation of IUGR 
Intrauterine growth restriction (IUGR) refers to the decline of the growth rate in utero, which may or 
may not result in a baby born small for gestational age (SGA) (Figure 2). Similarly a baby may be born 
IGF2 Leptin Insulin Thyroid 
Hormones 
Fetal tissue 
accretion 
Fetal tissue differentiation 
and maturation 
Fetal Growth 
*** 
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SGA with no reduction in the rate of growth: this would therefore not be as a result of IUGR. SGA is 
defined as a birth weight and / or length that is 2 standard deviations or less below the population 
mean; therefore 2.5% of all new-borns will meet the definition (Figure 2). The focus of this thesis will 
be on placenta mediated growth restriction.  
IUGR is associated with increased fetal and neonatal mortality and morbidity both in the short term 
(prematurity, cerebral palsy, intrauterine fetal death, neonatal death) and more long term (obesity, 
hypertension, type 2 diabetes)31–35. In the western world, the most common reason for IUGR is 
uteroplacental insufficiency36. Chromosomal abnormalities (5-20%), some fetal malformations (1-
2%), fetal infection (5-10%) and multiple gestation (3%) can be associated with a reduction in growth 
velocity of varying severity37. IUGR can be either symmetrical or asymmetrical. In symmetrical 
growth restriction, there is an equivalent reduction in growth velocity of both the fetal head 
circumference and abdominal circumference. In asymmetric growth restriction, there is a differential 
reduction in growth velocity of the fetal head in comparison to the abdominal circumference, 
favouring head sparing. Symmetry or asymmetry is thought to depend on the timing and origin of 
fetal growth restriction.  SGA accounts for approximately 10% of pregnancies and only a proportion 
of these are secondary to IUGR.  
 
 
Figure 2: Distinction between IUGR and SGA  
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This graph shows the difference between IUGR and SGA. SGA IUGR implies a reduction in growth velocity in 
utero. This can result in a fetus that is not SGA (red dotted line) or one that is SGA (blue solid line). In 
addition it is possible to be SGA with IUGR (green dotted line). IUGR –Intrauterine growth restriction; 
SGA  - Small for gestational age 
 
The diagnosis of IUGR is made after an insult has occurred.  Early recognition of risk factors for IUGR 
in pregnant women would allow for closer surveillance during gestation. Clinical risk factors however 
show a different impact for each individual case and are therefore not relevant as general screening 
tools. The current strategies employed in the evaluation of IUGR are covered below. 
1.2 The human placenta 
1.2.1 Normal placental development 
The placenta is a transient organ found in eutherian mammals with a role in providing nutrients for 
the developing fetus in addition to offering support and protection. The placenta exchanges a wide 
range of nutrients, endocrine signals, cytokines and growth factors between the mother and the 
fetus, thereby regulating intrauterine development. It is important to understand the normal 
development of this vital organ including its structure and function as it closely influences the 
growing fetus and resulting neonate. In an attempt to appreciate normal placental development, the 
anatomy of this organ will be described and the process of placental development covered below.   
Pregnancy is a complex process involving germ cell differentiation, gametogenesis, ovulation, 
fertilisation, implantation, decidualisation, placentation and parturition. Progress at each stage of 
human pregnancy is dependent upon the success of the preceding steps and requires careful 
coordination38. Fertilisation involves the formation of a diploid zygote from a haploid sperm and a 
haploid egg or ova. The zygote undergoes cell division resulting in differentiation into a blastocyst. 
 
Interaction between the blastocyst and maternal uterine luminal epithelium initiates the process of 
implantation, a process by which blood vessels of the embryo are brought into functional 
communication with the maternal circulation leading to the establishment of a functional placenta 
and pregnancy39. The trophectoderm forms the wall of the blastocyst whilst the mesoderm or inner 
cell mass forms the extra embryonic mesoderm (Figure 3). The trophectoderm differentiates into 
trophoblasts, which form the epithelial covering of the placenta. The inner cell mass (ICM) further 
differentiates into two distinct lineages, the epiblast and the primitive endoderm40. The epiblast 
gives rise to the fetus, the allantois, which forms the placental vasculature and the umbilicus, while 
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the primitive endoderm and trophectoderm give rise to the fetal membranes and the placenta 
respectively40.  The uterus undergoes developmental changes during the pre-implantation period, 
mediated by hormonal changes and signalling pathways41. These processes allow for the successful 
implantation of the blastocyst. Immediately after implantation, trophectodermal cells give rise to 
diverse trophoblast cell types. These include the lytic syncytiotrophoblast (ST) and the 
cytotrophoblast (CT) cells. CT are mononucleated cells that are able to proliferate and differentiate 
into other trophoblast subtypes, functioning as a precursor pool for the ST, which form the syncytial 
layer, and extravillous trophoblasts (EVT)42. CT may also acquire invasive properties, forming the 
EVT. These trophoblasts are able to invade and remodel maternal tissues and uterine spiral artery, 
reducing the resistance against blood flow that irrigates the fetus43,44. The syncytial layer has no 
proliferative capacity and is in intimate contact with maternal blood, participating in fetal 
nourishment, gas exchange and also playing important roles in other placental functions, mainly in 
protein biosynthesis (Figure 3).  
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Figure 3: Schematic showing placental development 
 A – Trophectoderm gives rise to the primitive syncytium after implantation. B– Proliferative CTB form primary 
villi. C – Tertiary villi are formed by migration of extraembryonic mesodermal cells. Endovascular extravillous 
trophoblasts are involved with immune function and remodelling of spiral arteries. AE, amniotic epithelium; 
CCT, cell column trophoblast; DF, decidual fibroblast; EB, embryoblast; EM, extraembryonic mesoderm; eCTB, 
endovascular cytotrophoblast; GC, giant cell; ICM, inner cell mass, iCTB, interstitial cytotrophoblast; LUE, 
luminal uterine epithelium; L, lacunae, pF placental fibroblast; PS, primitive syncytium; TE, trophectoderm; UG, 
uterine gland; uNK, uterine NK cell, UV, uterine vessel; vCTB, villous cytotrophoblast. Used with permission 
from the authors44. 
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Figure 4: Nutrient transporters in the syncytiotrophoblast 
Nutrient transporters are seen on both the maternal circulation facing microvillous membrane (MVM) and the 
fetal circulation facing basement membrane (BM). Maternal blood pools in the intervillous space and bathe 
the MVM. Transporters for the transfer of amino acids, glucose (GLUT), and fatty acids (FATPs) are expressed 
in both plasma membranes of the syncytiotrophoblast. 
 
Macroscopically the mature placenta consists of a discoid organ weighing approximately 500 grams 
at term40. The surfaces consist of a chorionic plate that faces the fetus and to which the umbilical 
cord is attached and the basal plate that abuts the maternal endometrium. Between these plates is 
the intervillous space into which 30 - 40 branched fetal villous trees project45. Each villous tree arises 
from a stem villous in the chorionic plate and branches to create a globular lobule 1 - 3 cm in 
diameter45. The centre of the lobule is located over the opening of a maternal spiral artery through 
the basal plate. Each lobule therefore represents an independent maternal- fetal exchange unit 
45,46(Figure 5).  
 
The final branches of the villus tree are the terminal villi. These are richly vascularised by fetal 
capillaries. The capillaries display local dilations or sinusoids, which bring the endometrium within 
close proximity to the trophoblasts. This area is thinned, thus reducing the diffusion distance 
between the maternal and fetal circulations to as little as 2-3 µm. Terminal villi are formed primarily 
from 20 weeks gestation onwards and further elaboration of the villous tree continues to term45.  
Syncytiotrophoblast 
FATP 
BM 
MVM 
Amino acid  
transporter 
GLUT 
Fetal Capillary 
Endothelial cell 
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The epithelial cover of the villous tree is the ST, a multinucleated syncytium presenting no 
intercellular clefts to the intervillous space. Because of its location, the ST is involved in syntheses 
and secretion of steroid and peptide hormones, protection against foreign organisms and active 
transport. An understanding of the placental morphology allows us to appreciate the various 
functions of the placenta covered below.  
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Figure 5: Depiction of the fetoplacental unit 
The macroscopic appearance is shown on the left with a zoomed in section of the intervillous space featuring 
the chorionic plate in contact with the fetus, stem and terminal villi and the basal plate in contact with the 
uterine myometrium. The trophoblast layer surrounding the villi are depicted with the fetal capillaries situated 
within the villi. CT, cytotrophoblast, ST, syncytiotrophblast 
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1.2.2 Placental function 
The window of implantation is a limited time span dependent on blastocyst competency and the 
receptive state of the uterus. Knowledge obtained from transgenic mouse models has helped to 
better understand the molecular basis of uterine receptivity, implantation and decidualisation in 
humans47. Oestrogen and progesterone coordinate uterine functions through multiple paracrine, 
juxtacrine and autocrine factors in a spatiotemporal manner. This is achieved through mediators 
such as cytokines. Furthermore sets of key regulatory transcription factors control the switch 
between trophoblast proliferation and EVT differentiation43. Key signalling pathways involved in 
trophoblast motility include growth factors such as Human Chorionic Gonadotropin (HCG), 
Endodermal Growth Factor (EGF) and Insulin-Like Growth Factor 2 (IGF2), which activate MAPK 
kinase and phosphoinositide 3-kinase signalling. Further investigations in human primary cultures as 
well as in trophoblast cell lines have provided evidence for an autocrine role of canonical Wnt 
signalling in human trophoblast proliferation and invasion48.  
One of the major functions of the human placenta is the capacity to synthesise important hormones 
and other mediators, crucial for gestational success. Placental-related hormones play important 
roles during several gestational events. The ST layer is the main source of placental hormones. Other 
trophoblast phenotypes however, may also produce some placental hormones and affect the 
gestational course. The hormones produced by the EVT are thought to contribute to vascular and 
uterine tissue remodelling and regulate EVT migration and invasion26.  
Human chorionic gonadotropin (HCG) is one of the most important hormones in pregnancy. From 
day 8 after fertilisation, HCG is detectable in maternal serum and its levels peak in week 10 of 
gestation, thereafter decreasing slowly until the end of pregnancy49. The HCG receptor is expressed 
in the CT, ST and EVT. HCG mediated effects are essential for the maintenance of early pregnancy.  
HCG also promotes in-vitro human CT differentiation into ST, by activating the LH-HCG receptor and 
consequently Protein Kinase A (PKA) pathway50. Progesterone is mainly produced from the corpus 
luteum during the first few weeks of pregnancy. At 6-8 weeks, after HCG concentration decreases, 
the placenta is the main source of progesterone due to the formation of the syncytial layer. 
Progesterone has important functions in menstrual bleeding but additionally in placentation and 
preparation of the mammary gland for lactation. Oestrogens play several roles during pregnancy 
including in angiogenesis.  Adipocyte derived signalling proteins including leptin, adiponectin and 
resistin have roles to play in nutrient transport, immune modulation and placentation27,51,52.  
28 
 
The functions of the placenta are closely orchestrated by regulatory factors, which may be 
influenced by the intrauterine milieu. In this way the placenta carries out its functions efficiently 
while maintaining pregnancy to term. As part of the placenta’s function it may undergo adjustments 
in order to keep the intrauterine environment optimum for fetal growth and development. Below 
we address some of these adaptations that take place during gestation. 
1.2.3 Placental adaptations 
Placental adaptation is required in humans in order to maintain pregnancy while adjusting to 
changes during gestation. Changes in supply capacity of the placenta can be triggered by intrinsic 
(genetic and developmental) or extrinsic (environmental) factors that regulate intrauterine 
development11. As the placenta is the main interface between the mother and fetus, it receives and 
integrates a wide range of fetal and maternal signals that ultimately determine its plasticity. 
Placental adaptations occur as gestational age advances. Fetal growth increases exponentially with 
fetal weight increasing most dramatically during the last half of gestation. On the other hand utero-
placental growth slows down or ceases during the last half of gestation whilst placental transport 
capacity keeps pace with the continually increasing demands of the fetus53. This increase in placental 
function can be primarily attributed to increases in vascularity and blood flow together with 
associated morphological changes. In addition, in both humans and mice there is a progressive 
thinning of the trophoblast barrier layer with gestational age thus decreasing diffusion distance for 
passive exchange54. Furthermore there is a continual increase in fetal capillary surface area54,55. Fetal 
signalling of demand for maternal nutrients is an important regulator of placental transport capacity, 
most prominently in late gestation as shown by animal studies56,57. 
Further evidence for placental plasticity is seen in the adaptive changes noted with pathology in this 
organ. Morphological adaptations seen in the placenta include changes to placental vasculature as 
seen in Doppler flow changes with fetal growth restriction58, changes to interhaemal barrier 
thickness as seen in alteration of microvillous membrane (MVM) thickness in human pregnancies at 
high altitudes16,17,59 and changes to cellular composition as seen in mouse studies with both 
maternal diet manipulation and knockout models60,61. These changes result in modulation of 
nutrient transport within the placenta. Functional adaptations include alterations to nutrient 
transport channels or changes in placental hormone secretion.  
The underlying molecular mechanisms involved in the placental adaptive response are not well 
understood, however recent work suggests that nutrient sensing pathways and epigenetic 
mechanisms may play significant roles in these processes11. Changes in gene expression associated 
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with placental adaptive responses can be attributed, at least in part, to epigenetic alterations. 
Epigenetics refers to the study of molecular modifications that influence gene activity and 
chromosome structure without a change to DNA sequence. These modifications are heritable and 
result in a gene expression state that persists through over cell generations62. One of the best-
studied epigenetic modifications is DNA methylation, which involves the addition of a methyl group 
at 5’ position of a cytosine adjacent to a guanine (CpG dinucleotide)63. Recent genome-wide studies 
of DNA methylation in the human placenta have revealed large-scale differences in DNA methylation 
levels through the three pregnancy trimesters, with an overall progressive increase in average 
methylation being observed with increasing gestational age64. Work has shown an association 
between patterns of DNA methylation and infant growth resulting in the identification of 22 critical 
loci that are highly predictive of IUGR65. DNA methylation profiles were obtained on 206 term 
human placenta samples. This work was carried out to add to existing work on imprinted genes and 
therefore did not identify DLK1 or IGF2. With this work it was not possible to determine whether 
altered profiles of DNA methylation are in response to the intrauterine environment or whether the 
changes were causative for IUGR. In addition there was an overrepresentation of CpG island 
associated loci. Gene regulatory methylation events may occur in regions outside CpG islands. These 
data together suggest that methylation status in the human term placenta may function both as a 
marker of intrauterine environment and also play a critical functional role in fetal development and 
growth. The placenta therefore undergoes adaptive changes to ensure optimal fetal growth and 
development within the constraints of prevailing intrauterine conditions.   
In addition to the control of transcription at DNA level (DNA methylation), epigenetic regulation 
controls transcription at protein level (histone modification) and at RNA level (non-coding RNAs). 
The nucleosome is a protein complex, consisting of two copies of four core histones (H2A, H2B, H3 
and H4) around which the DNA is wrapped. The N-terminal of nucleosomal histones undergoes 
epigenetic modifications including methylation, acetylation, phosphorylation and ubiquitinylation. 
These modifications are accomplished by a range of enzymes. Proteins can recognise and bind to 
these specific modifications and exert an effect on gene activity. Majority of the transcripts from the 
transcribed mammalian genome consists mainly of non-coding (nc) RNAs. These nc RNAs can act in 
cis (same chromosome) or in trans (different chromosome/ mature RNAs in cytoplasm). This method 
of epigenetic regulation is seen later in the section about DLK1. 
 1.2.4 Abnormalities in placental development 
Pregnancy is programmed as a dynamic process and any major aberration in its normal course will 
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either terminate pregnancy at the time of insult or perpetuate defects throughout pregnancy. These 
defects are reflected in aberrations in decidualisation, placentation and intrauterine embryonic 
growth, manifesting as intrauterine growth restriction (IUGR), preeclampsia, miscarriages and/or 
preterm birth.   
Several knockout mouse models helped to define propagation of early defects during the course of 
pregnancy. Mutant mice have been seen to have abnormalities such as defective uterine receptivity 
or deferred implantation. This deferred implantation results in embryo overcrowding, conjoined 
placenta, placental insufficiency, fetal growth restriction, fetal resorption and reduced litter size47. 
Further studies have shown that suboptimal decidualisation can lead to premature decidual 
senescence, resulting in preterm birth with neonatal death or in abnormal guidance of placentation, 
which can lead to shallow invasion. A number of genes have been identified as being essential for 
the placentation process in these knockout models with expression in human myometrium 
suggesting conservation of the genes of interest47.  
1.2.4.1 Consequences of abnormal placentation in human pregnancies 
Placental adaptation has been mentioned previously as part of the physiological adjustments 
required by the placenta in normal pregnancy. The nature of the placental changes associated with 
adaptive responses depends on a variety of factors, which include the severity of the environmental 
challenges, the timing and duration of the challenge and possibly the sex of the offspring. Adaptive 
responses may, however, be blunted or compromised if there is a need to activate severe stress 
responses aimed at safeguarding maternal-fetal survival. Preeclampsia and fetal growth restriction 
are disorders that are rooted in defects of early placental development 66. These defects include 
poor trophoblast uterine invasion, impaired transformation of the uterine spiral arteries to high 
capacity and low impedance vessels, and abnormalities in the development of chorionic villi.    
Defective uterine receptivity, implantation and / or decidualisation can lead to infertility. 
Furthermore, implantation outside the window of receptivity can lead to misguided embryo 
placement, resulting in placenta praevia, ectopic placentation (placenta accreta) or placental 
insufficiency resulting in intrauterine growth restriction and /or preeclampsia43,67. Implantation 
beyond the normal window can also give rise to spontaneous abortion, miscarriage and recurrent 
pregnancy loss68. The underlying mechanisms and pathways involved in the process of placentation 
are poorly understood. A better understanding of this process could lead to more definitive 
management of fetal growth restriction and other gestational conditions associated with aberrant 
placentation, during pregnancy.  
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1.2.5 Clinical impact of placental pathology  
 As seen in the previous sections, the process of placentation involves carefully orchestrated events 
that are required to take place at the appropriate time in order to achieve normal gestation. 
Variations in the process can lead to pathology, which inevitably can affect the pregnancy and the 
resulting neonate. These can present in a variety of ways during pregnancy. However due to the 
nature of pregnancy, the methods currently available tend to detect pathology late in gestation once 
an insult has occurred. This is true for IUGR where interventions usually take place once a reduced 
fundal height has been detected during antenatal follow up. This is usually in the third trimester for 
most pregnancies.  
1.2.5.1 Current antenatal evaluation of IUGR 
Clinical examination is unreliable in detecting SGA fetuses on its own. Diagnosis of a SGA fetus 
usually relies on ultrasound measurement of fetal abdominal circumference or estimation of fetal 
weight69. A number of surveillance tests are available, including cardiotocography, Doppler and 
ultrasound to assess biophysical activity. At booking, those identified as being at risk are offered 
appropriate surveillance (Table 1). Those identified to have major risk factors are referred for serial 
ultrasound measurement of fetal size and umbilical Doppler flow assessment from 26-28 weeks of 
pregnancy 69(Table 1). In addition those with three or more minor risk factors are referred for 
uterine artery Doppler at 20-24 weeks gestation69. Several biochemical markers have been 
investigated as screening tests for SGA. Systematic reviews found low predictive accuracy for alpha-
fetoprotein, elevated hCG and inhibin A, low unconjugated estriol and the combined triple test to 
predict a SGA fetus70,71. Low levels of first trimester PAPP-A and /or hCG were associated with an 
increased frequency of adverse obstetrical outcome including a SGA infant72.  
Early ultrasound features of IUGR include a reduction in growth velocity and oligohydramnios. The 
Doppler ultrasound sampling of uterine arteries is a useful non-invasive method for the assessment 
of the interaction between the fetal and maternal haemodynamic compartment. Doppler studies 
typical of uteroplacental insufficiency include uterine artery notches, absent or reversed end- 
diastolic flow in the umbilical artery and fetal arterial redistribution. Similar features are seen in fetal 
abnormality or infection, but usually the uterine Doppler values and amniotic fluid volume are 
normal.  Women with an abnormal uterine artery Doppler at 20 – 24 weeks (PI > 95th centile) and/ or 
notching should be referred for serial ultrasound measurement of fetal size and assessment of 
wellbeing with umbilical artery Doppler commencing at 26-28 weeks of pregnancy.  Additionally 
serological screening for congenital infections and karyotyping (especially in the presence of 
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structural anomalies) is carried out in cases of severe SGA (AC and EFW < 3rd centile). The combined 
approach using clinical information, serum markers, and biophysical parameters such as ultrasound, 
showed increased predictive relevance73.   
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Risk category Definition of risk 
Maternal RF 
Age   
 
Parity 
BMI 
 
 
Maternal substance exposure 
 
 
IVF 
Exercise 
Diet 
 
Previous Pregnancy History 
Previous SGA 
Previous still birth 
Previous pre-eclampsia 
Pregnancy interval 
 
 
Maternal Medical History 
SGA 
Hypertension 
Diabetes 
Renal disease 
APLS 
 
Paternal Medical History 
SGA 
 
Maternal age ≥ 35 
Maternal age ≥40 
Nulliparity 
BMI <20 
BMI 25 – 29.9 
BMI ≥30 
Smoker 
Smoker 1-10 cigarettes/day 
Smoker ≥ 11 cigarettes/ day 
Cocaine 
IVF singleton pregnancy 
Daily vigorous exercise 
Low fruit intake pre pregnancy 
 
Previous SGA baby 
Previous still birth 
Pre-eclampsia 
Pregnancy interval < 6 months 
Pregnancy interval ≥ 60 months 
 
 
Maternal SGA 
Chronic hypertension 
Diabetes with vascular disease 
Renal impairment 
Antiphospholipid syndrome 
 
 
Paternal SGA 
 Table 1: Antenatal risk factors for intrauterine growth restriction  
Table detailing risk factors for SGA available from history at booking (usually at ≤ 12 weeks 
gestation). Major risk factors are shown in bold. APLS – Antiphospholipid syndrome; RF – Risk 
factors; SGA – Small for gestational age. (RCOG Green-top Guideline No. 31) 
 
The main focus of research is towards a first trimester diagnosis, as the optimal period during which 
a prophylactic treatment is effective in optimising placentation is before 16 weeks gestation. A 
biomarker in early pregnancy with a strong positive predictive value for IUGR could potentially 
reduced the incidence if IUGR thereby reducing complications in the resulting neonate.   
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1.3 Genomic imprinting 
The placenta is a plastic organ that responds to fetal signals in addition to changes in the 
intrauterine environment. These adaptive changes result in alteration to the morphology and 
function of the placenta. These events are thought to be effected by a change in gene expression, 
which can be attributed, at least in part, to epigenetic alterations65,74.  
 Genomic imprinting is an epigenetic process by which a gene is differentially expressed according to 
the parental origin75. Imprinted genes, which are abundantly expressed in the placenta, are often 
found in clusters with gene expression being regulated by imprinting control regions (ICR). DNA 
methylation is the best characterised epigenetic modification and involves the addition of a methyl 
group to cytosines that precede a guanosine in the DNA sequence (the CpG dinucleotide)76. All ICRs 
identified are differentially methylated regions (DMR) on the two parental chromosomes. These 
differential methylation marks are acquired in the developing gametes and are maintained in the 
developing embryo throughout life77. In addition to allele-specific methylation, non-coding (nc) RNAs 
also regulate imprinting. They are able to regulate expression of genes on the same chromosome 
(when acting in cis), on different chromosomes (when acting in trans) or in mature mRNA in the 
cytoplasm78. These epigenetic marks acquired during development result in fetal programming and 
have an effect in later life. 
1.3.1 Developmental origin of Health and Disease 
Thorough comprehension of the processes occurring in utero during gestation is important, as the 
quality of life of a growing fetus in utero is likely to be a major determinant of quality of life in 
adulthood. Epidemiological studies suggest that suboptimal growth during the fetal period 
predisposes to specific diseases later in life including adult onset hypertension, type 2 DM and 
coronary heart disease79. This is known as the ‘thrifty phenotype’ hypothesis and refers to the fetal 
response to inadequate nutrient supply and consists of decreased muscle mass, insulin resistance, 
decreased capillary network and an increased stress response80. In this setting, subsequent 
abundance of nutritional supplements may predispose an individual to the development of the 
metabolic syndrome which consists of centripetal fat accumulation, insulin resistance, glucose 
intolerance, hyperlipidaemia and hypertension. Many studies worldwide have confirmed the initial 
epidemiological evidence. These include a follow up study carried out on a population in 
Hertfordshire born between 1911 and 1930 (5585 women and 10,141 men) with weight at birth and 
one year of age recorded. Standard mortality ratio was seen to fall with increasing birth weight in 
both sexes81. Further studies have shown an association with low birth weight and syndrome X (type 
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2 DM, hypertension and hyperlipidaemia). In this study the risk for syndrome X was 10 times greater 
in cases of lower birthweight82. Interestingly, a genome - wide association study (GWAS) has linked 
the DLK1 locus, an imprinted gene, with Type 1 Diabetes Mellitus (T1D)83. A newly identified locus 
with the strongest association with T1D susceptibility occurred in an imprinting region on 
chromosome 14q32.2 marked by SNP rs 941576 A>G. This region contains paternally derived (DLK1, 
RTL1, DIO3) and maternally derived (MEG3, MEG8) as covered in section 1.4 below. Of the 
paternally expressed genes, only DLK1 has a strong functional candidacy. It is most strongly 
expressed in the human heart, pancreatic islet cells, pituitary tissue, ovaries, placenta and testes. In 
addition it encodes a membrane bound protein, which can be cleaved to form fetal antigen 1 (FA1). 
FA1 is involved in the differentiation of many cell types including pancreatic beta cells. FA1 is also 
involved in haematopoiesis including differentiation and function of B-lymphocytes and has been 
shown to increase expression of pro-inflammatory cytokines in human bone marrow mesenchymal 
stem cells and promote B cell proliferation in human peripheral blood. In this way, variation in the 
expression of DLK1 could alter susceptibility to T1D, which is caused by autoimmune destruction of 
insulin producing beta cells in the pancreas.  
Additionally, a retrospective study compared birth weight to the risk of non-fatal cardiovascular 
disease with a finding of RR 1.49 (95% CI 1.05 – 2.10) for BW < 2268 grams. This is in comparison to 
RR of 1 for BW > 3175 – 3836 grams; 0.96 (0.8 – 1.15) for BW > 3856 – 4356 and 0.68 (0.46 – 1) for 
BW > 4356 grams84. The biological basis for suggesting developmental plasticity as an influence on 
the risk of disease derives from numerous studies in animals in which dietary, endocrine or physical 
challenges induce persistent changes in cardiovascular and metabolic function in the offspring. 
Embryos of pregnant rats fed a low-protein diet during the preimplantation period showed altered 
development in multiple organ systems and in addition the offspring had reduced birth weight, 
relatively increased postnatal growth and adult onset hypertension85 Further studies on rats 
involving the administration of a  low-protein diet resulted in a reduction in the number of nephrons 
and hypertension86. Furthermore, in a rat model of nutritional imbalance, the offspring of rats fed an 
imbalanced diet during pregnancy later had elevated blood pressure, reduced nephron number and 
increased responses to salt loading as well as reduced vasodilator function in systemic arteries87.  
Exposure to under nutrition in early gestation, as seen in studies of the Dutch Hunger Winter, a 
severe wartime famine at the end of WW II affecting the western part of The Netherlands, has been 
associated with subtle changes in methylation at three DMRs in different imprinted clusters in blood 
samples of affected when compared to unaffected siblings62,88.  In animal studies, manipulation of 
the maternal diet during pregnancy leads to a persistent shift in average DNA methylation levels of 
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specific genes in offspring resulting in permanent changes in coat colour or tail shape89,90. The 
findings in the human and animal studies support the theory that intrauterine disturbances in early 
gestation may cause changes in later life, mediated by epigenetic modification during development. 
Early gestation is a sensitive period with carefully orchestrated events controlled at various levels. A 
better understanding of these events and the factors that influence outcome is necessary in order to 
reduce the risk of long-term sequelae.  
1.3.2 Imprinting and fetal growth 
Both animal knock out studies and known human syndromes with growth phenotypes, secondary to 
imprinting defects, together support a role for imprinted genes in fetal growth. Several uniparental 
disomies (UPD) have been identified in humans, with specific phenotypes and they include Prader-
Willi (PWS) and Angelman syndrome (AS)91, Beckwith-Wiedermann syndrome (BWS), Silver-Russell 
syndrome (RSR)92,93 and transient neonatal diabetes mellitus (TNDM)93, maternal and paternal 
UPD14 syndromes94 and psuedohypoparathyroidism95. Insulin growth factor 2 (Igf2), one of the first 
imprinted genes to be identified, is expressed from the paternally inherited copy, resulting in 
placental stunting and fetal growth retardation on deletion and fetal growth enhancement on 
overexpression96,97. Subsequent studies confirmed that overexpression of Igf2 via loss of imprinting 
through deletion of imprinting controlling sequences can cause placentomegaly as well as fetal 
overgrowth98. In the human overgrowth syndrome BWS, human IGF2 was found to undergo loss of 
imprinting in a subset of patients further supporting this finding. Knockout of the maternally 
expressed, paternally imprinted Grb10 results in mice that are 30% heavier than wild type99, further 
supporting a role for imprinted genes in fetal growth. 
Knockout or transgenic mouse models for most imprinted genes result in growth defects. For 
instance deletion of the Peg1/Mest paternal allele causes fetal and placental growth retardation in 
mice100. In addition deletion of the paternal allele of Peg3 results in fetal growth retardation and 
placental stunting101. Additionally the maternally expressed/paternally silenced genes Phlda2, 
Slc22a1, Cdkn1c, Kcnq1 and Ascl2 are clustered on an imprinting domain on mouse chromosome 778.  
Paternal deletion of a cis acting differentially methylated DNA element, Kvdmr1, causes coordinate 
loss of imprinting and overexpression of all these genes and the resulting conceptus show IUGR78. 
Furthermore placental overgrowth is seen after gene deletion and growth retardation after loss of 
imprinting. Specific genes such as H19/ IGF2 have been studied in the context of growth restriction, 
demonstrating differential methylation of the imprinting control regions in placentas from growth-
restricted infants65. A number of other imprinted loci such as PHLDA2, IKL2, NNAT, CCDC86, PEG10, 
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PLAGL1, DFKR24, ZNF331 and CDKALI have been shown to demonstrate differential expression 
between growth restricted and non-restricted infant placentas102–104.   
The role of imprinting genes in non-syndromic human IUGR is poorly understood. A number of 
studies have attempted to explore expression of imprinted genes in IUGR compared to normal 
pregnancies. One study105employed microarrays to interrogate differential expression of both 
imprinted and non-imprinted genes between 14 IUGR and 15 non-IUGR placenta. 7% of the 
differentially expressed genes were imprinted, making up 22% of all the imprinted genes. Another 
study observed that 17% of 52 imprinted genes were significantly differentially expressed in cases of 
IUGR compared to normal pregnancies104.  
It appears that overall however; imprinted genes are dysregulated in IUGR and therefore have an 
important role to play in intrauterine growth. One such gene is Delta-Like homologue 1 or DLK1. This 
is an imprinted gene, paternally expressed with the maternal allele remaining silent. This gene is 
described further in section 1.4. Further support for the role for imprinted genes and IUGR is noted 
in a recent GWAS106. GWAS data for birth weight was combined in 153, 781 individuals representing 
multiple ancestries from 37 studies across three components including the UK Biobank. 60 loci 
associated with birth weight at genome wide significance (P < 5 x 10 -8 ) were identified. 53 of these 
loci were novel. Previously reported loci included CCNLI-LEKRI, HMGA2, CDKALI, ADCY5, ADRBI, 
LCORL and 5q11.2. The novel loci identified included INS-IGF2, IGF2BP3, IFF1R, PLAC1, IGF1 and RB1. 
DLK1 association signals approached significance with P = 5.6 x 10-8 . The group felt that despite the 
large sample size, analyses were underpowered and much larger samples are required for definitive 
analysis. 
1.4 DLK1 
1.4.1 Background 
DLK1 is expressed in an imprinting cluster on the long arm of human chromosome 14 (14q32.2)107. 
This domain contains the protein coding genes DLK1, RTL1 and DIO3 expressed from the paternal 
allele and the imprinted maternal allele expressed genes GTL2/MEG3, MEG8 and antisense 
RTL1108,109 which are non-coding RNAs. DLK1 also known as Pref-1 was cloned and characterised 
during experiments using 3T3-L1, an adipocyte cell line110. Here it was found to regulate adipocyte 
differentiation.  
Imprinting expression is controlled by a primary imprinting control region (ICR), intergenic 
differentially methylated region (IG-DMR)111,112 located between DLK1 and GTL2/MEG3 (Figure 6), 
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which is usually only methylated on the paternal allele112. The imprint on IG-DMR is acquired during 
gametogenesis on the male germ line and subsequently influences methylation on the paternal 
allele of a somatic DMR within the GTL2/MEG3. The unmethylated IG-DMR on the maternal allele is 
associated with expression of GTL2/MEG3 and RTL1 which represses expression of DLK1 and 
RTL1 in cis113.   
39 
 
 
Figure 6: Imprinting cluster on human chromosome 14
Paternally expressed genes are shown in blue whilst the maternally expressed genes are shown in red. Two 
DMRs are shown; with methylation of the germ line IG-DMR and the MEG3 DMR. Used with permission from 
the authors.113
1.4.1.1 DLK1 structure 
DLK1/PREF1 as characterised by Smas et al consists of a 1589 bp transcript110. It has also been 
referred to as zona glomerulosa specific mRNA114 and Fetal antigen 1(FA1)115 depending on the 
context in which it was isolated. The cell surface transmembrane protein has a predicted structure 
which consists of six tandem EGF-like repeats in an extracellular domain110. These begin shortly after 
the signal sequence and encompass 60% of the protein (Figure 7). A juxtamembrane region precedes 
the transmembrane domain and in addition the short cytoplasmic domain is rich in serine, threonine 
and proline and contains several potential phosphorylation sites110. The DLK1 transcript undergoes 
alternate splicing, with four major isoforms of the transcript detected116 (Figure 7).  The longest form 
(PREF-1A) is the most abundant whilst in-frame juxtamembrane deletions result in three other 
transcripts (PREF - 1B, C and D)116 Figure 7. The tandem nature of the repeats shows similarities to 
the EGF-like repeats of the Drosophila cell fate determining proteins Notch and Delta110. DLK1 exists 
as both a transmembrane and soluble form117 with cleavage of the full-length protein resulting in a 
soluble product of 50 kDa 116. This cleavage is carried out by a protease, TNF-α converting enzyme 
(TACE), in the juxtamembrane domain118. The soluble form of DLK1 shares functions with the 
membrane bound full-length molecule117. Based on these data we can postulate that DLK1 achieves 
its actions in both a juxtacrine and paracrine manner in utero.  
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Figure 7: DLK1 structure   
Isoforms of DLK1 showing soluble, cleavable forms of the molecule (PREF 1A and B) along with the membrane 
bound forms (PREF 1C and D). The full-length molecule is seen at the top of the diagram with the signal 
peptide, EGF-like repeats, TACE cleavable site and transmembrane domain depicted. Used with permission 
from M. Charalambous. 
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1.4.1.2 DLK1 and growth  
Knockout studies in mice have highlighted the importance of DLK1 in growth and 
development.119,120.DLK1 null mice display pre- and postnatal growth retardation, eyelid and skeletal 
abnormalities such as asymmetrical junction of ribs to sternum and fusion of ribs119. In addition, 
DLK1 null mice were seen to have abnormal placenta including placenta hypoplasia and abnormal 
vasculature120–122. Conditional deletion in mouse pancreatic beta cells, pituitary somatotropes and 
fetal endothelial cells of the placenta labyrinth did not cause pathology in knock out mouse models 
however120. This suggests that DLK1 has tissue specific functions during development. 
In humans, maternal uniparental disomy of chromosome 14 (mUPD14)123, paternal deletions94 and 
loss of methylation at the IG-DMR124 result in a phenotype of low birth weight, hypotonia, early 
puberty and markedly short adult stature. This constellation of abnormalities constitutes a condition 
known as Temple syndrome (TS)124and is associated with dysregulation of expression of genes at the 
imprinted locus on chromosome 14. mUPD is the most widely recognised cause of TS and results in 
loss of expression of all paternally expressed genes and overexpression of maternally expressed 
genes within this imprinting domain123,125–132. Imprinting in this cluster is controlled by an IGDMR, 
which is located between DLK1 and GTL2/ MEG3 and is normally methylated only on the paternal 
allele. The function of the unmethylated IGDMR on the maternal allele is to regulate DLK1 and RTL1 
expression in cis. In addition to mUPD (which accounts for 70-80% of cases), dysregulation of 
expression of genes at this imprinted locus can arise from: copy number change (10%); mutation of 
expressed coding genes (<2%) and due to epigenetic error (12%)113. The study of rare TS patients 
with copy number changes enabled Kagami et al133to confine the region of interest to a 108kB 
paternal deletion involving DLK1 and GTL2/ MEG3. Two patients had many features of TS but stature 
was more severely affected in a third reported case with a larger deletion (411 kB), which included 
RTL1 (but not DIO3). Silencing mutations have not been reported in humans, but in the mouse null 
mutations of DLK1 and RTL1 inherited from the male have TS features. Furthermore, paternal 
uniparental disomy (pUPD) causes thoracic skeletal anomalies, polyhydramnios, placentomegaly and 
limited survival. The hypothesised cause is overexpression of paternally expressed RTL1, due to the 
absent regulatory effects of maternal RTL1as134. The 14q32-imprinted region is dosage sensitive with 
deletions of different critical regions causing mUPD14 and pUPD14 like phenotypes.     
In a mouse model, hypomethylation of the IG-DMR resulted in reduced expression of DLK1135 
therefore all mechanisms are predicted to result in reduced expression from the paternal allele.  In 
addition, the abnormalities seen in pUPD14 highlight the importance of DLK1 in intrauterine 
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development94,136.  
1.4.1.3 DLK1 during intrauterine development 
DLK1 has an important role to play in embryonic development and expression is pronounced in the 
embryonic period in both mice and humans, thereafter decreasing during fetal development137,138. In 
the human placenta, expression is seen in the mesenchymal fibroblasts adjacent to fetal endothelial 
cells138. DLK1 was mainly seen in early gestation apart from in human fetal chondroblasts and human 
endothelial cells where expression is seen all through gestation138. These findings suggest a role for 
DLK1 in cell differentiation, which mainly takes place in early gestation.   
 
A group in Denmark, Floridon et al, measured maternal serum DLK1 levels in pregnant women and 
demonstrated a rise in DLK1 concentrations from 17 weeks gestation of pregnancy, with a peak in 
late gestation at approximately 36 weeks138. Prior to 17 weeks gestation, levels were comparable to 
males and the non-pregnant female population138. This pattern has been replicated in mouse 
studies139. As the weight of the fetus increases most dramatically during the last half of gestation140, 
the peak in DLK1 suggests that higher levels may be required during this period of rapid growth and 
placental adaptation.  
 1.4.2 Current knowledge with regards to DLK1 function  
DLK1 has been shown to be involved in the proliferation and differentiation of various precursor 
cells110,141.  Experiments using pre adipocyte cell lines (3T3-L1) have demonstrated a role in the 
inhibition of adipocyte differentiation110,142. DLK1 has been found to play an important role in lipid 
metabolism and recent mouse knock out models have demonstrated an increase in lumps of white 
adipose tissue (WAT) and abnormal body composition in virgin dlk1 null mice143. WAT is associated 
with increased leptin, which is an important in utero hormone with a function in fetal growth by 
influencing nutrient transporters in the placemt144. DLK1 has also been identified as a regulatory 
factor for human mesenchymal stem cell differentiation to osteoblasts and adipocytes145–147. Further 
functions have been suggested in haematopoiesis, neuronal cell regeneration and in 
thermoregulation in brown adipose tissue (BAT). More recently DLK1 has been found to have a 
function in differentiation of pancreatic ductal cells into insulin producing pancreatic β cells148. DLK1 
is thought to exert most of its actions in these tissues by activating the mitogen-activated protein 
kinases (MAPKs) signalling pathways and has been found to increase phosphorylation of ERK in 
adipose tissue149. Understanding the mechanisms of action of DLK1 in other tissues will allow us to 
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begin to elucidate its role in intrauterine growth. This knowledge may lead to the recognition of 
therapeutic targets for intervention. 
Current work using genetically modified mice that lack a functional copy of Dlk1 has been carried out 
to determine the source of maternal DLK1 in pregnancy. This confirmed that the maternal DLK1 
levels are elevated during pregnancy as previously shown by other groups including Bachmann et al. 
Serial measurement of maternal plasma DLK1 in crosses of mice where the mother, the conceptus or 
both were unable to express Dlk1 were conducted. DLK1 was detected at high levels in maternal 
plasma only if the conceptus retained the ability to express Dlk1. This suggests that the conceptus is 
the source of elevated maternal plasma DLK1 in pregnancy. Additional models of Dlk1 dosage 
manipulation were utilised to distinguish whether the placenta or embryo was the source of 
maternal plasma DLK1. Their data showed that the source of circulating maternal plasma DLK1 is the 
embryo, not the placenta143. This remains to be confirmed in the human fetoplacental unit.   
1.5 Thesis Rationale 
I was initially involved in the design of a clinical study for a laboratory project already underway 
within our group. This was a project evaluating fetal adrenal gland development150. The design of the 
project involved the recruitment of participants from the fetal medicine unit. The case group was 
selected to include a group of pregnant women with placental dysfunction and a control group of 
women with uncomplicated pregnancies. A systematic review and meta-analysis151examined the 
diagnostic accuracy of first trimester (12 weeks gestation) uterine artery Doppler measurements in 
predicting pre-eclampsia. This revealed that a uterine artery pulsatility index (PI) greater than 1.96 in 
the 1st trimester suggested an increased risk of pre-eclampsia. The specificity for predicting early 
onset pre-eclampsia using this screening method was high. First trimester uterine artery Doppler is 
therefore a useful tool to stratify women by risk status and target them for appropriate clinical 
management and identify higher risk individuals for research purposes. Pre-eclampsia is a condition 
associated with placental dysfunction, and therefore presumed placental insufficiency, which is 
associated with IUGR. 
A research study carried out in the antenatal clinic at the Royal London Hospital from 2011 revealed 
that 20% of women scanned at 12 weeks have PI measurements greater than 1.96. Out of this 
group, 35% of those with a PI greater than 1.96 go on to develop pre-eclampsia. The remaining 65% 
of women screened have uncomplicated normal pregnancies. This work has since been published.152 
This screening method, carried out as part of an on-going research study in the Fetal Medicine Unit, 
was used as a selection tool to enrol women in my study.  The finding of a PI greater than 1.96 at 12 
44 
 
weeks was predicted to provide both a cohort of women with normal pregnancies and a cohort that 
go on to develop placental dysfunction. The advantage of using this starting point for selection and 
enrolment is that both cohorts will receive exactly the same follow up during the course of the 
study. In addition this screening method was thought to provide a group of participants with a 
common mechanism for IUGR. I therefore decided to take advantage of this unique cohort, to assess 
DLK1 as a potential biomarker for IUGR as it was going to be possible to collect measurements 
associated with fetal growth parameters prospectively in addition to maternal parameters.    
The main cause of intrauterine growth restriction is placental insufficiency. The mechanism behind 
this pathology is poorly understood. The process appears to involve placental adaptations in 
response to both fetal and maternal signals. I decided to focus on DLK1 in this work as evidence from 
animal knockout studies119,153 and human Temple syndrome123 suggest an important role for this 
protein in intrauterine growth. Furthermore, DLK1 is widely expressed during the embryonic period 
in humans and in addition expression has been seen in trophoblast cells within the labyrinth in 
mouse placenta143. My work therefore involved interrogating the function of DLK1 in utero by 
comparing maternal serum levels to fetal growth parameters. In addition, as uteroplacental 
insufficiency is an important cause of fetal growth restriction, I embarked on placental studies to 
further attempt to understand what occurs in the placenta in cases of abnormal DLK1 production.  
In the first instance I carried out an analysis of maternal serum DLK1 levels in a cohort of women 
recruited prospectively from our Fetal Medicine Unit (FMU) at the Royal London Hospital as 
described above. These women also underwent serial ultrasound scans for fetal growth parameters 
along with other ultrasonic assessments of fetal growth. As DLK1 was shown to increase insulin 
pancreatic β cells148 , I hypothesise that DLK1 will effect some of its function on fetal growth through 
insulin either directly or by influencing the bioavailability of IGF and leptin. As insulin is found to 
peak in the third trimester during pregnancy, and has been shown to increase nutrient transporters 
in the placenta 6,154, these effects are likely to result in an overall increase in fetal size due to mass 
accumulation and tissue growth, and may be characterised by an increase in abdominal 
circumference clinically. This is the most sensitive measure of fetal growth by ultrasound 
assessment155. Maternal serum DLK1 levels in the third trimester should therefore be predictive of 
abdominal circumference.  
 
In addition, animal knock out studies have shown that dlk1 null mice have reduced size due to a 
reduction in skeletal length143. With this in mind, in addition to the finding in human embryos of 
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DLK1 immunostaining in resting chondrocytes within the epiphyseal disc138 , I hypothesise that 
maternal serum DLK1 levels will be predictive of long bone growth in utero, demonstrated by 
femoral length growth. 
Further experiments were carried out on placentas collected from this cohort of women at delivery. 
The placental histomorphometrics were carried and compared to clinical information collected from 
the cohort and maternal serum DLK1 levels. As DLK1 has been found to be expressed in the 
trophoblast layer of cells in animal studies143, I hypothesise that immunostaining of the placenta will 
reveal DLK1 positive cytotrophoblast and syncytiotrophoblast group of cells and that DLK1 will have 
a role in trophoblast invasion. Cases with low DLK1 levels will therefore show histological evidence 
of maternal vascular malperfusion of the placenta bed such as distal villous hypoplasia, accelerated 
maturation of the villi, decidual arteriopathy and the presence of multinucleated trophoblastic giant 
cells in the maternal decidua. Furthermore, as trophoblast cells within the placenta are secretory 
cells with an endocrine function, serum DLK1 levels will affect placental function as will be indicated 
by a positive relationship between serum DLK1 levels and placental weight/ volume. I further 
hypothesise that DLK1 regulates placental growth. 
Given what we know about fetal growth and the role of DLK1 in this process, this research was 
carried out in an attempt to ascertain whether maternal serum DLK1 could be used to predict 
adverse outcomes in pregnancy with particular reference to IUGR. Taking into consideration what 
we know about placental development, fetal growth and the role of DLK1 in growth, this project was 
focused to evaluate a possible role for DLK1 as a biomarker for intrauterine growth, especially when 
severe. The development of a biomarker, particularly in early pregnancy can provide a non-invasive 
screening tool for pregnancies that need closer surveillance in the way of more frequent ultrasound 
scans. In addition once the mechanism of DLK1 in intrauterine growth is better understood, it may 
be possible to intervene therapeutically in cases where abnormal DLK1 levels and growth have been 
identified.  
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Chapter 2 Materials and methods 
2.1 Circulating DLK1 concentrations during pregnancy 
2.1.1 Description of the clinical cohort  
Following full ethical approval of the study protocol obtained from the Brighton and Sussex NREC,      
recruitment of participants attending routine antenatal scans (12 weeks ultrasound) between 
February 2013 and April 2014 at the Fetal Medicine Unit (FMU) occurred. This pilot study involved 
prospective follow up of participants antenatally leading to a cohort of normal pregnancies and 
those complicated by IUGR secondary to placental insufficiency (Figure 8). Inclusion criteria are 
shown in table 2. Subjects were recruited from the following cohort of patients: Pregnant women 
who present to the antenatal clinic at the Royal London Hospital and have already consented to 
have their routine 12 week scan performed by a senior obstetric doctor as part of a study examining 
Doppler measurements. Patients who were found to have PI measurements greater than 1.96 
(carried out as part of an on-going obstetric study) on their 12 week dating scan were identified as 
eligible for this study by the doctors carrying out the scan. Either our obstetric collaborators or 
myself provided written information about my study during this 12-week antenatal appointment 
once the patient gave verbal consent. Written informed consent from those patients who agreed to 
participate in the study was obtained once again either by myself or our research nurse at the time 
of the anomaly scans between 18-22 weeks. Data was collected and added to a database created on 
a secure research laptop, which was stored in a locked drawer in a locked office at the Centre for 
Endocrinology. These participants were followed up on 4 separate occasions antenatally as seen in 
the flow diagram (Figure 6) with two further instances of contact at delivery and 24 to 48 hours 
following delivery. At each visit, participants underwent blood sampling for DLK1 levels and 
metabolic markers. Further serum was taken for storage. In addition, the participants underwent an 
ultrasound scan where fetal growth parameters (abdominal circumference, bipareital diameter and 
femoral length) and umbilical artery Doppler were carried out. Maternal clinical parameters were 
measured at each visit including blood pressure and weight and clinical information including 
medication history, underlying illness and pregnancy complications were obtained. At delivery, the 
placenta was obtained on average after twenty minutes after delivery for further macroscopic and 
microscopic analysis. Further serum samples were obtained 24 – 48 hours after delivery. Any 
complications arising during labour or thereafter were noted. The serum obtained was analysed for 
DLK1 levels using Enzyme- Linked Immunosorbent Assay methods. The primary endpoint for this 
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study was the correlation of DLK1 serum levels with fetal growth. Secondary endpoints included the 
association of DLK1 levels with neonatal and pregnancy outcome as DLK1 was postulated to act as a 
biomarker to signify intrauterine pathology.  
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Figure 8: Recruitment and prospective follow up of participants  
Flow diagram showing recruitment and prospective follow up of participants. USS, Ultrasound Scan 
Table summarising inclusion and exclusion criteria for study 
Inclusion criteria: 
• Women found to have PI greater than 1.96 on ultrasound at 12 weeks gestation. 
• Singleton pregnancies 
 
Exclusion criteria: 
• Other coexistent maternal medical conditions (chronic hypertension, diabetes, thyroid 
disease, adrenal disease, renal disease). 
• Congenital abnormalities of fetus or chromosomal anomalies. 
• Maternal exposure to psychotropic medication. 
• Heavy smoking or alcohol abuse in pregnancy. 
• Multiple pregnancies. 
• Maternal infection with TORCH infections (Toxoplasmosis, rubella, CMV, syphilis), or human 
immunodeficiency virus. 
 
Table 2: Inclusion and exclusion criteria for study. 
 PI  - pulsatility index; TORCH – Toxoplasmosis, Other (syphilis, varicella zoster, parvovirus B19), 
Rubella, Cytomegalovirus and Herpes. 
 
Recruitment resulted in a cohort of women from an ethnically diverse background. 40 suitable 
patients were initially recruited for the study whilst attending for anomaly scans at the Fetal 
Medicine Unit of the Royal London Hospital. 33 of these patients completed the study. Of the 
patients failing to complete the study, three were lost to follow up (one delivered abroad whilst 2 
13 weeks
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delivered in other hospitals), whereas 4 decided to discontinue the study, as they felt unable to 
attend for the additional visits required outside their routine care. Our patient cohort is comparable 
to the general population (Table 2). The average age in our cohort is comparable to that of pregnant 
women in the UK and Wales. The average booking BMI in our study group reflects the rising BMI 
seen in pregnant women in the UK with maternal obesity accounting for 15.6% of pregnancies in 
England156. Our final cohort consisted of 17 (51.5%) recruits with a normal BMI (range 19.39 – 
24.46), 13 (39.3%) overweight (BMI range 25.2 – 29.17) and 3 (0.1 %) obese recruits (BMI range 
33.55 – 41.79). Most of the cohort delivered at term. There were however two preterm deliveries at 
26.9 and 33.6 weeks gestation.  With the former being spontaneous and the later secondary to an 
induction of labour for IUGR. Four of the neonates in the cohort had pregnancies complicated by 
IUGR with birth weight SDS ranging between -3.3 and -2 (Figure 8).  
Table showing maternal characteristics for pregnancies complicated by IUGR  
Maternal 
age 
BMI Ethnicity Parity Complications BW in 
grams 
(SDS) 
BL in cm 
(SDS) 
GA 
28 28.1 Caucasian G3, P1* Poor previous 
obstetric 
history. 
Commenced 
on aspirin 
2420 (-
2.4) 
44.8 (-
4.6) 
39 
28 26.84 Bengali G4, P1 * IOL for absent 
EDF 
1720(-
3.3) 
44.5 (-
1.98) 
37 
23 20 Bengali G2, P0* IOL for absent 
EDF 
1340 (-2) 40.5 (-
1.72) 
33 
33 20.2 Caucasian G1, P0 SVD 1860 (-
2.88) 
 37 
Table 3: Pregnancies complicated by IUGR in the RLH cohort. 
 
3 of the 4 pregnancies were complicated by multiple miscarriages - asterix. * - 2 miscarriages. G - Gravida, P - 
Parity; IOL - Induction of labour; EDF - End Diastolic Flow; SVD – Spontaneous Vaginal Delivery 
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2.1 Participant demographics 
Characteristic Mean ± SD Range N 
Age, years  26.8 ± 6.1 17.0 - 37.0 33 
BMI  25.4 ± 5.3 18.8 - 41.8 33 
Gravidity  1 1.0 - 4.0  33 
Parity  0 0.0 - 2.0 33 
Gestational age, weeks  
   Visit 1 
   Visit 2 
   Visit 3 
   Visit 4 
 
20.35 ± 0.68 
28.07 ± 0.75 
34.42 ± 0.75 
38.09 ± 0.62 
 
19.29 - 22.57 
26.29 - 29.86 
33.00 - 36.14 
36.00 - 39.71 
 
31 
32 
28 
23 
Gestation at delivery, weeks  39.33 ± 2.83 26.86 - 42.14 31 
Birth weight, grams 3006 ± 650 950 - 3680 31 
Birth weight SDS -0.698 ± 0.913 -3.30 - 0.840 31 
Maternal ethnicity    
White European   10 
South East Asian   10 
Far East Asian   4 
Afro Caribbean   3 
Mixed   3 
Black African   2 
Other   1 
Table 4: Royal London Hospital participant characteristics  
Table showing participant characteristics in the Royal London Hospital cohort. Mean and std dev are shown 
with a range of values between the minimum and maximum. The number of participants is shown in the last 
column. 
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2.2 Measurement of Fetal growth and assessments for signs of fetal 
growth restriction 
2.2.1 Measurement of fetal growth parameters 
Two FMU fellows, independently, using the Voluson 730 and E8 systems (Voluson Expert; 
Milawaukee, WI) performed fetal Ultrasound Scans (USS). BPD, HC, AC and FL in addition to 
assessment for signs of fetal growth restriction were carried out at four different time points during 
gestation. USS assessments also included estimation of gestational age and fetal weight. The 
methodology used is described below. 
2.2.1.1 Measurement of BPD and HC 
The BPD is the maximum diameter of the transverse section of the fetal skull at a level of the parietal 
eminences. Measurements were made using thalamic views. This view includes a rugby-football-
shaped skull, rounded at the back (occiput) and more pointed at the front (synciput), a short midline 
equidistant from the proximal and distal skull echoes, the cavum septum pellucidum bisecting the 
midline one- third of the distance from the synciput to the occiput, the thalami and the basal 
cisterns. A brief description of BPD and HC measurements using thalamic views are to follow below. 
To begin with, a longitudinal section of the fetus is obtained. The transducer is then rotated through 
90° to obtain a transverse section of the fetal head ensuring that the midline is centrally placed. A 
section of the anterior horns is obtained and on making a slight rotation of the probe towards the 
fetal neck, the basal cisterns are imaged. This is then followed by a sliding movement of the probe 
downwards, towards the fetal body, allowing the lower body of the cavum to be just visible in 
addition to the optimal view of the thalami. The BPD is then measured on the frozen image. Callipers 
are placed on the outer border of both the proximal and distal parietal bones, at the widest 
diameter. The HC is measured from the same view as the BPD. The two-diameter method is used 
which involves the measurement of the BPD and Occipito-frontal diameter (OFD). The machine’s 
software then calculates the HC using the formula πd derived from the formula for the 
circumference of a circle (2πr) 
 HC = 3.14 (BPD + OFD) / 2 
2.2.1.2 Measurement of AC 
The AC was measured using specified landmarks. A longitudinal view of the fetus showing the heart 
and the fetal bladder was obtained after which the transducer was moved laterally until the spine 
was visualised. The transducer was then rotated through 90° at the level of the fetal stomach to 
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obtain a cross-section. The circumference of the abdomen was measured using a two-diameter 
method. The anteroposterior diameter (APAD) was measured from the fetal spine to the anterior 
abdominal wall. The transverse abdominal diameter (TAD) was then measured across the widest 
part of the abdominal circumference section at 90° to the APAD. The machine’s software was then 
used to calculate the AC using the formula πd, derived from 2πr as per the HC above:    
AC = 3.14 (TAD + APAD)/2 
2.2.1.3 Measurement of FL 
The femur can be measured from 12 weeks to term. Measurement of the FL was undertaken 
typically after measuring the AC.  The probe was moved caudally from the AC section until the iliac 
bones were visualised. At this point, a cross section of one or both the femurs was seen. The upper 
femur was selected for measurement. Whist keeping the anterior femur in view, the probe was then 
rotated slowly until the full length of the femur was obtained. The measurement of the femur was 
made from the centre of the ‘U’ shape at each end of the bone to obtain the length of the 
metaphysis. Measurements were obtained from three separate images of the same femur. All three 
measurements above were then plotted on growth charts in order to ascertain that the 
measurements were within the normal range for gestation. Both BPD and FL were used to estimate 
gestational age independently, with the help of dating tables. In addition, estimated fetal weight was 
derived from the BPD, HC, FL and AC using software on the machine, which is based on the Shepard 
and Hadlock equations. 
2.2.2 Assessment for features of fetal growth restriction 
Ultrasound features of uteroplacental insufficiency including placental abnormality (lakes, 
calcification, jelly-like consistency) and reduction in amniotic fluid volume were assessed. These 
assessments were made alongside Doppler assessments. Methodology for this is described below. 
2.2.2.1 Doppler flow assessments 
Uteroplacental waveforms were acquired from the uterine artery by means of colour, pulsed 
Doppler ultrasound. To begin with colour flow imaging was used to identify the bifurcation of the 
common iliac artery in longitudinal section. The probe was moved medially angled slightly towards 
the symphysis pubis to reveal the uterine artery just medial to the bifurcation, as it ascends towards 
the uterus. On obtaining an optimal waveform, the maximum frequency follower was turned on and 
the image frozen once the automatic calculations were displayed. Both the pulsatility index (PI) and 
resistance index (RI) were calculated automatically by the machine. PI and RI represent an index of 
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impedance to flow. High resistance patterns were described as bilateral notches with mean RI > 0.55 
or unilateral notch with mean RI>0.65. Doppler findings typical of uteroplacental insufficiency 
include: uterine notches, absent / reversed end-diastolic flow in the umbilical artery and arterial 
redistribution.  
Umbilical artery waveforms were also obtained. These waveforms reflect downstream placental 
vascular resistance. Colour flow imaging was used to identify the umbilical cord at the placental 
insertion. Once the waveform from the umbilical arteries was seen, the maximum frequency 
follower was switched on and the image frozen once the automatic calculations were displayed. The 
PI was derived from the average of three waveforms. In addition, the frequency in end diastole was 
recorded as either normal, absent or reversed.  In the case of loss of end-diastolic frequencies, the 
signal was rechecked from another site. 
2.1.2 Collection and storage of serum samples  
Approximately 5 mls of blood was obtained by venepuncture from the participants for analysis of 
DLK1 levels. Samples were taken into a yellow top serum separating tube. These samples were then 
spun within 3 minutes of venepuncture. The spinning was carried out using a cold centrifuge, at a 
temperature of 4°C and a speed of 3000rpm for a total of 10 minutes. Once separation of serum 
from the plasma was obtained, serum was collected into microcentrifuge tubes in triplicate and 
stored transiently in a -20°C freezer at the hospital prior to transfer in dry ice to the Centre for 
Endocrinology lab, where they were stored at -80°C.  
2.1.3 ELISA assay for DLK1 levels 
Stored serum samples were analysed for DLK1 levels. This was carried out using a sandwich Enzyme 
Linked-Immunosorbent Assay (ELISA) for quantitative determination of human DLK1 in biological 
fluids from Adipogen®.  Sample aliquots were brought to room temperature and diluted (1 in 10) 
using ELISA buffer. 100 µl of each sample was then added to a pre-coated 96 well plate as per the 
manufacturer’s instructions. Each sample was analysed in duplicate. The assay procedure was 
carried out according to the supplier’s instructions. Each run included a standard curve: 
Standard 0  0ng/ml 
Standard 1  0.469ng/ml 
Standard 2  0.938ng/ml 
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Standard 3  1.875ng/ml 
Standard 4  3.75ng/ml 
Standard 5  7.5ng/ml 
Standard 6  15ng/ml 
Standard 7  30ng/ml 
Each standard was added to the wells in duplicate. 10X ELISA buffer was diluted using deionised 
water at a dilution of 1:10 prior to use. 10X Washer buffer was also diluted using deionised water at 
1:10 to obtain a 1X solution. DLK1 is recognized by the addition of a purified polyclonal antibody 
specific for DLK1 (Detection Antibody). After removal of excess polyclonal antibody, HRP conjugated 
anti-IgG (HRP) is added. Following a final washing, peroxidase activity is quantified using the 
substrate 3, 3’, 5, 5’-tetramethylbenzidine (TMB). The intensity of the colour reaction is measured at 
450 nm after acidification and is directly proportional to the concentration of DLK1 in the samples.  
 
2.2 Placental studies 
2.2.1 Sampling from the placenta at delivery 
Table 3 shows the features of the placentas collected from the RLH cohort. We were able to obtain 
placenta from 25 out of the 33 participants. Out of the 8 missed placentas, 4 participants delivered 
in hospitals out of area whilst the other 4 delivered in emergency situations with no time to inform 
the research team of delivery. Most of the neonates were delivered at term as can be seen from the 
table. Majority of the umbilical cords were seen to have 3 vessels with only 1 out of the 25 placentas 
obtained demonstrating a 2-vessel cord. In addition, 60% of the placentas were found to have a 
peripheral cord insertion; 24% marginal and 16% exhibited a central insertion. There was no 
significant difference seen in maternal DLK1 serum levels with the varying cord insertions at 18 – 21; 
26-29; 32-34 and 37-39 weeks gestation. See Appendix  
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N = 25 Mean ± std dev  Range 
GA  39.63± 1.732 33.57 – 42.14 
Neonatal weight (grams) 3074 ± 589.7 1340 – 3680 
Placental weight (grams) 426.6 ± 122.8 168 – 762 
Feto - placental ratio 7.645±2.359 3.56 – 16.83 
Placental length (mm) 189.3±64.26 130 - 480 
Placental width (mm) 152.8 ±21.95 110 – 192 
Placental depth (mm) 26.48 ± 5.108 20 – 40 
Cord length (mm) 377.3±152.5 15 -750 
Cord diameter (mm) 15.92±16.22 3 – 90 
   
Table 5: Placental and neonatal characteristics  
Table showing neonatal and placental characteristics from the cohort. GA – Gestational Age.  
 
In the first instance, on attendance to the delivery, cord blood was collected from both the umbilical 
artery and umbilical vein. These blood samples were then spun in a cold centrifuge as described 
above prior to storage transiently in a -20°C freezer at the Royal London Hospital if out of hours for 
no more than 24hours, or collection in dry ice prior to transfer to a -80° C freezer at the Centre for 
Endocrinology, QMUL. Placental biopsies were then obtained from five peripheral regions (P1 – 5) 
and one central (C)(Figure 7) using a 5mm punch biopsy (Schucho Miltex Biopsy Punch). At each 
region, two biopsy samples were obtained. One for DNA and the other was placed in RNA later 
(R0901 Sigma RNAlater ®) for future RNA extraction. In addition umbilical cord samples were 
obtained for both DNA and RNA extraction. Umbilical cord samples were collected as 
representations of fetal tissue as we know that both the fetus and umbilical cord arise from the ICM 
developmentally. These samples were also subsequently stored at -80°C. 
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Figure 9: Obtaining placental biopsy tissue at delivery  
Diagram showing areas of placental biopsy (P1-5; C) and umbilical cord sampling. Dashed line represents 
section of umbilical cord obtained for sampling. P1 to 5, Peripheral; C Central. Note that the central biopsy was 
obtained 2 cm from the cord insertion to allow for histological examination of the cord insertion.  
2.2.2 Morphological characterisation of placenta 
After the biopsy samples were obtained, the placenta was stored in 4% formaldehyde for 24 hours 
prior to fixing in paraffin. The placenta was then characterised and sampled as per the Amsterdam 
Placental Workshop Group Consensus Statement157. In the first instance placental weight was 
obtained and included the placenta trimmed of extraplacental membranes umbilical cord. Prior 
biopsy sampling was noted along with any disruption of the basal plate. The placenta was then 
measured in three dimensions: the maximal linear dimension (length), the greatest dimension of the 
axis perpendicular to this linear measurement (width), and the mural minimal and maximal 
thickness. This was then followed by description of the cord which included the average diameter of 
the cord, length, site of insertion in relation to the centre /margin of the placenta (distance between 
insertion and the nearest placental margin), the presence of strictures, and whether cord appears to 
be hypocoiled or hypercoiled. Insertion is further described as central, marginal (<1cm from the 
nearest margin),velamentous (insertion into the fetal membranes) and peripheral (<3cm from the 
nearest margin).The membranes were then described including a description of the colour/opacity 
and completeness.  
Subsequent to the description, the cord, membranes and placental disk were sampled. Four blocks 
were obtained as a minimum: 1 block included a roll of the extraplacental membranes from the 
rupture edge to the placental margin (including part of the marginal parenchyma) and 2 sections 
from the umbilical cord, one from the fetal end and another approximately 5 cm from the placenta 
insertion end; and three other blocks containing the full thickness section of normal appearing 
placenta parenchyma. The full- thickness samples were taken from within the central two-thirds of 
P1 
P5 
P4 
P2 
P3 
C 
Placenta 
Placenta vessels 
Umbilical cord 
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the disc and include one adjacent to the insertion site (Figure 7). A further block was obtained if 
there was pathology noted on macroscopic inspection. Each block had an ID number automatically 
assigned to it.  
In the first instance, H&E staining of the blocks above was carried out as described in section 2.2.4. 
The histology was reported both by myself and perinatal pathologist from the Royal London 
Hospital, Dr Irene Scheimberg. We were both blinded to clinical details and identity of the 
participant whilst reporting.  The slides were reviewed systematically as shown in table 4.  Examples 
of H&E staining and from the cohort are shown in Figure 10 - 12.  
 
Figure 10: Macroscopic findings on examination of placenta 
72% of placentas were normal. Haematoma was seen in 2 (8%) whilst 1 placenta was seen to have a thrombus 
with no other changes.3 (12%) were seen to have focal fibrosis. Of these 1 showed fibrosis with no other 
changes, 1 showed fibrosis in addition to an infarct whilst one showed fibrosis in the presence of a thrombus. 
 
Figure 11: Placental sampling  
Diagram showing transverse section through placenta. A1= cord + membranes; A2 = cord insertion; A3 = 
peripheral section; A4 = random peripheral section.  
Fetal 
membranes 
Fetal side  
Maternal Side  
Decidua 
Umbilical cord 
A1 
A1 
A2 A3 A4 
Normal
Haematoma
Thrombus
Fibrosis
Fibrosis + infarct
Fibrosis + Thrombus
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Compartment Features 
Villi Maturation (accelerated/ delayed/ normal) 
Distal villous hypoplasia – present/ absent 
Avascular villi   - present/ absent 
 
Decidua Decidual arteriopathy  - present / absent 
 - acute atherosis 
- fibrinoid necrosis 
- absence of spiral artery remodelling 
 Persistence of endovascular trophoblast 
Presence of MTGC 
Fetal Membranes                                
 
Other 
Infection/ inflammation (see grading) 
 
Thrombosis – present/ absent/ location 
Hemorrhage – present / absent/ location 
Intramural fibrin – present / absent/location 
Table 6: Methodology for placental histology characterisation  
Table showing features reviewed when carrying out histological staging.  The villi, decidua and fetal 
membranes were examined. Other abnormalities outside these areas were also noted. Grading of infection/ 
inflammation is shown in table 2.4. MTGC – multinucleated trophoblastic giant cells.  
 
Staging and Grading of the Maternal and Fetal Inflammatory Responses in Ascending 
Intrauterine Infection 
Maternal Inflammatory Response 
Stage 1 – acute subchorionitis or chorionitis Grade 1 – not severe as defined 
Stage 2 – aute chorioamnionitis: PMN 
leukocytes extend into fibrous chorion and /or 
amnion 
Grade 2 – severe: confluent PMN leukocytes or 
with microabscesses 
Stage 3 – necrotizing chorioamnionitis: 
karyorrhexis of PMN leukocytes, amniocyte 
necrosis, and/or amnion basement membrane 
hypereosinophilia 
 
Fetal Inflammatory Response 
 
Stage 1 – chorionic vasculitis or umbilical 
phlebitis   
Stage 2 – involvement of the umbilical vein and 
one or more umbilical arteries 
Stage 3 – necrotizing funisitis 
Grade 1 – not severe as defined 
Grade 2 – severe: near – confluent intramural  
PMN leukocytes with attenuation of vascular 
smooth muscle 
Table 7: Histological staging and grading of placenta  
Table showing criteria used for grading and staging inflammation. It is divided into maternal and fetal 
inflammatory response. PMN – Polymorphonuclear. Adapted from Khong et al, Arch Pathol Lab Med:140, 
2016157.  
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Figure 12: Maturation of placental villi  
Picture showing instances of appropriate maturation -  A (at 39 weeks gestation). Terminal villi are seen as 
typical of term placenta; delayed maturation B - (centre at 40 weeks gestation). Although placenta is term, 
note the presence of intermediate villi and a paucity of terminal villi; and accelerated maturation - C (right at 
33 +3 weeks gestation). Note the presence of small terminal villi despite a gestational age of 33 weeks.
Figure 13: Chorioamnionitis compared to normal placenta  
An example of normal fetal membranes is shown on the left (A). The amnion and chorion are depicted and are 
well defined with a normal morphology of cells. On the right (B) we see an infiltration of inflammatory cells in 
the both the chorion and amnion as seen in chorioamnionitis with loss of the clear depiction of the amnion 
and chorion.
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Figure 14: Normal decidua compared to one with MTGC 
Figure showing H&E of the maternal decidua. Normal decidua is seen on the left (A) with extravillous 
trophoblasts and decidual stromal cells. On the right (B) we see clusters of MTGC depicted by a large black 
arrow and labels. MTGC – multinucleated trophoblastic giant cells
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2.2.3 Early gestation tissue 
Early gestation umbilical cord and placental samples were obtained from the Medical Research 
Council (MRC) / Wellcome Trust funded HDBR (London), with appropriate maternal consent and 
approval from the local National Health Authority Ethics Committee. The Brighton and Sussex REC 
approved the experimental protocol for this research. The samples were transported from the clinic 
to the HDBR resource, staged, dissected, fixed in formalin and embedded in paraffin prior to 
preparation in histology cassettes. The age of the fetal samples were estimated following the 
guidelines of Hern (Hern 1984) and the embryos were staged using the Carnegie Staging 
classification system (O’Rahilly & Müller 2010). A snip of tissue from each sample was taken to 
perform cytogenetic analysis to determine the mitotic karyotype. All samples had a normal male or 
female karyotype. Samples were then transported to our lab in the cassettes where slides were 
prepared for immunohistochemical studies. 
 
2.2.4 Immunohistochemistry studies  
Immunohistochemistry was carried out on the placental slides using the EnVision FLEX ™ system 
from Dako. As paraffin is insoluble in water, most staining methods require it to be removed. The 
slides underwent dewaxing and deparaffinisation in xylene twice and alcohol twice (95%, 70% 
ethanol) respectively prior to rehydration by washing in tap water for 5 minutes. Antigen retrieval 
was carried out using a High pH target retrieval solution (50X) after dilution to 1X. Retrieval was 
carried out by placing slides in target retrieval solution into a water bath, heated to 99°C over 40 
minutes. This results in heat induced epitope retrieval. The slides were then cooled in the high pH 
solution at room temperature over a period of 20 minutes. A PAP pen was then used to draw around 
the specimen on the slides before carrying out washes using Washer Buffer (20X) after dilution to 
1X. Three washes were carried out each lasting 3 minutes each prior to addition of EnVision™ FLEX 
Peroxidase – Blocking Reagent for 5minutes. This is a phosphate buffer containing hydrogen 
peroxide, 15mmol/L NaN3 and detergent. This was followed by a further 3 washes in Washer Buffer 
lasting 3 minutes each. Antibody was then diluted in Dako Antibody Diluent and incubated on slides 
for 40 minutes followed by a further three washes in Washer Buffer. EnVision™ FLEX + Rabbit 
LINKER/ Mouse LINKER (depending on the primary antibody) was then added to the slides and 
allowed to incubate for 20 minutes. The LINKER results in signal amplification of primary antibodies. 
After three washes in Washer Buffer, EnVision™ FLEX HRP (Horseradish peroxidase) reagent was 
added to the slides and allowed to incubate for 30 minutes. This reagent consists of a dextran 
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backbone to which a large number of HRP molecules and secondary antibody molecules have been 
coupled. Following three washes using Washer Buffer, EnVision™ FLEX DAB Chromogen was then 
used for visualisation. DAB, a concentrated diaminobenzidine solution, needs dilution in EnVision™ 
FLEX Substrate Buffer, containing hydrogen peroxide, before use. Dab + Substrate Buffer was added 
to the slides for 5 minutes before washing in tap water for a further 5 minutes. The substrate system 
produces a crisp brown end product at the site of the target antigen. Haematoxylin was used for 
counterstaining. The slides were dipped in haematoxylin for three minutes prior to rehydration in 
tap water. Washes were then carried out in alcohol and xylene prior to covering the slides with glass 
slips using DPX mounting medium (Lamb laboratories) to preserve staining.  Visualisation and 
imaging was carried out using the NanoZoomer-2.0 HT Digital Slide Scanner (Hamamatsu) and 
Panoramic Viewer (3DHistech) software, and the Leica DMR Light microscope, Leica DC200 digital 
camera, and Leica DC Viewer software.  
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Antibodies used for immunohistochemistry 
Ab                       Antigen               Species                 Company             Dilution              Catalogue 
number 
1°                        DLK1                     Rabbit                   Abcam                  1 in 200                            
ab110636 
 
1°                        CD31                     Rabbit                  Abcam                   1 in 100                            
ab28364 
 
1°                     Cytokeratin 7         Mouse                  Dako                      1 in 100                            M7018 
                         Clone OV-TL 12/30  
          
Table 8: Primary antibodies used in immunohistochemistry methods  
List of primary antibodies used for IHC studies along with dilutions. 
2.2.5 Haematoxylin and Eosin staining 
Slides were dipped for 3 minutes in haematoxylin (Lamb Laboratories) and thereafter left under 
running water for 3 minutes. They were then dipped in ethanol 3 times (95%, 70% and 50%), 
followed by another 2 minutes under running water. This was followed by dip in Eosin for 30 
seconds (Lamb Laboratories), and four dips in alcohol (100% X2 ethanol, 95% and 70%) and washes 
in xylene. Excess xylene was wiped from the back and edges of the slides, and they were covered 
with glass slips, using DPX mounting media (Lamb Laboratories) to preserve the staining.  
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2.2.6 Staging of immunohistochemistry studies 
Figure 15: Staging and grading of DLK1 staining in placental villi 
Picture showing examples of intensity of DLK1 staining in trophoblasts and fetal endothelial cells. A:  a+++ in FE 
and Tr;  B: a +++ in FE and b++ in Tr;  C: a+++ in FE and a ++ in Tr; D: c+ in both FE and Tr. FE (fetal endothelial); 
Tr (Trophoblast). Trophoblasts are indicated by a black arrow and fetal endothelial cells by a red arrow.  
 
Reporting was carried out independently, prior to comparing findings using criteria in table 6. In 
addition we were blinded to clinical information.  
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Criteria Feature recorded 
Location Fetal Endothelial Cells 
Trophoblast Cells 
 Decidua 
Pattern of staining A – Diffuse 
 B – Moderate 
 C – Focal 
Intensity +++ Strong 
 ++ Moderate 
 + Weak 
Table 9: Staging and grading of staining intensity in immunohistochemistry methods  
Table highlighting criteria used to stage immunohistochemistry. 
2.2.6 Finnish Cohort  
In view of the results obtained from the pilot data, we proposed to extend our analysis to a larger 
cohort of participants. These participants were recruited between 2006 and 2007 with longitudinal 
follow up thereafter, at Kuopio University Hospital (Kuopio, Finland) and from local maternity units 
in Kuopio, for other studies including a study on minipuberty158. These patients were stratified into 
normal pregnancies, those at risk of IUGR secondary to placental insufficiency and those at risk of 
imminent premature delivery. 173 participants were initially recruited with 113 completing the 
study. 91 participants were included in our study after exclusion of twin and other multiple 
deliveries (Table 7). This cohort is larger and consists of a more homogenous group of participants. 
SGA was defined as sex and gestational age specific birth height < -2SD, according to the new Finnish 
birth size reference159. Within the selected cohort for analysis in this group, the SGA group had 
features of fetal growth restriction caused by pathology in utero and therefore IUGR. We are 
grateful to have received serum samples serially collected from this cohort along with clinical 
information, antenatal ultrasound scan data and placental blocks from our Finnish collaborators. 
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Serum samples received were taken in the second and third trimester, at delivery and on day one 
post delivery. In addition participants ELISA assays and immunohistochemical studies were carried 
out on the Finnish samples as detailed above for the RLH cohort. 
In view of the findings in our pilot study locally, advantage was taken of existing serum samples that 
had been collected from a cohort of participants antenatally for a study on mini puberty as 
described in the previous chapter..  
These investigations were carried out to strengthen findings from the pilot studies. From my IHC I 
hope to show that DLK1 is expressed in trophoblast cells, which are known to have a function in 
secreting endocrine hormones. In this way DLK1 will influence placental function and fetal growth by 
regulating hormones with important functions in growth.   
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Characteristic Mean/ Median ±std dev 
(95% CI)/ Range 
N 
Age, years 31.4 ± 5.28 (29.9 – 32.41) 69 
Weight, Kg 65.18 ± 12.51 (62.15 – 68.21) 68 
Height, cm 165.7 ± 6.12 (164.3 – 167.2) 69 
BMI 23.99 ± 4.66 (22.85 – 25.12) 67 
Weight increase 12.36 ± (11.09 – 13.62) 58 
Gravidity 2 (1 – 13) 69 
Parity 1 (0 – 10) 68 
Average gestational age at 2nd 
trimester visit 
21.46 ± 2.87 (20.15 – 22.76) 21 
Average gestational age at 3rd 
trimester visit 
31.6 ± 4.32 (30.49 – 32.7) 61 
Gestational age at birth, 
weeks 
36.97 ± 4.63 (35.85 – 38.08) 69 
Birth weight, grams 2815 ± 1051 (2562 – 3067) 69 
Birth weight SDS 
SGA 
AGA 
-0.82 ± 1.39 (-1.15 - -0.49) 
 
69 
18 
50 
Birth length, mm 46.41 ± 5.64 (45.06 – 47.77) 69 
Birth length SDS 
SGA 
AGA 
-0.95 ± 1.59 (-1.34 - -0.57) 69 
15 
53 
Occipitofrontal Circumference 
(cm) 
32.85 ± 4.1 (31.87 – 33.83) 68 
Occipitofrontal Circumference 
SDS 
-0.7 ± 1.44 (-1.05 - -0.34) 64 
Sex  Male 37 
Female 32 
Table 10: Participant characteristics for the Finnish cohort  
Table showing participant characteristics within the Finnish cohort along with details of resulting neonates
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2.3 Genetic studies on embryonic representative tissue to assess DLK1 
expression in IUGR when compared to normal pregnancies  
2.3.1 DNA extraction from umbilical cord 
Frozen umbilical cord sections were brought to room temperature. After removal of the outer 
maternal sheath (Figure 14), 200mg of tissue was collected from the internal Wharton jelly 
containing the umbilical vessels. This sample, representative of fetal tissue, was used for genomic 
DNA extraction. (Figure 8) 
 
 
                                                
The outer maternal sheath 
was removed prior to using the rest of the umbilical cord, representative of embryonic tissue, for extraction of 
genomic DNA. 
DNA was extracted from umbilical cord tissue using chloroform: isomylalcohol.  In the first instance 
50mls of buffer was made up containing 2.5 ml of 50mM Tris pH 8.0, 2.5ml of 100mM EDTA, 1 ml 
100mM NaCl, 5ml 1% SDS and 39.5ml MilliQ water.  200 mg of umbilical cord tissue was obtained as 
detailed above. This was placed into a 1.5ml microcentrifuge tube after which 525µl of buffer was 
added. This was followed by the addition of 35 µl of 10mg/ml Proteinase K (molecular grade, Sigma-
Aldrich) followed by incubation at 55 °C overnight.  Proteinase K is used to dissociate the tissue to 
allow DNA to become available. In addition it releases DNA from histones.  On day 2, Digestion of 
RNA was carried out by addition of 2 µl of 0.2mg/ml RNase A and incubating at 37°C for 1 hour. 
Polysaccharide removal was then carried out by the addition of 200 µl 5M NaCl and gently mixing. 
This was followed by the addition of 700 µl of chloroform: isoamylalcohol and mixing gently on an 
orbital shaker for 2 hours. The samples were then centrifuged at 10000rpm for 10 minutes. The 
Wharton Jelly 
Allantoic Duct 
Umbilical Vein 
Umbilical arteries 
Maternal Sheath 
Figure 16:  Transverse section through umbilical cord
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upper aqueous layer was removed into a new tube and the organic and inter-phases discarded. 700 
µl of isopropanol was added to the mixture prior to mixing gently by inverting the tube. The 
precipitated DNA was visible at this stage. Further centrifugation was carried out at 10000rpm for 10 
minutes. This resulted in the formation of a DNA pellet. The pellet was washed for 1 hour at 4°C with 
300 µl 70% Ethanol. After removal of ethanol, 200 µl of TE buffer (1ml of 1M Tris pH 8.0, 40 µl of 
0.5M EDTA, 99 ml MilliQ Water) was added. DNA was then resuspended by mixing on a roller 
overnight.  
2.3.2 PCR studies of DLK1 
Each 20µl reaction contained 1µl DNA, 0.5 µl dNTPs (10mM A+C+G+T), 1 µl primers (10 µM Forward 
+ Reverse) see table, 2 µl 10X PCR buffer, 0.2 µl TAQ DNA Polymerase (Thermus aquaticus) and 15.3 
µl distilled water. 
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Standard PCR program: 
Cycle Temperature Time
1 94°C 5 minutes Strand separation = 
denaturation of the 
hydrogen bonds within 
the double stranded 
DNA  
 
 
 
 
 
 
 
 
 
40 cycles 
94°C 30 seconds Further strand 
separation  
59°C 30 seconds Annealing - allows the 
primers to bind to a 
section of the single 
stands of DNA for which 
they have been 
specifically designed. 
This temperature may 
vary slightly depending 
on the Tm (melting 
temperature) of the 
primers  
72 °C 1 minute Extension - Taq DNA 
polymerase binds to the 
primers and uses dNTPs 
as building blocks to 
enzymatically synthesise 
a complementary strand 
of DNA. The newly 
formed DNA contains 
one strand of parental 
DNA, and one newly 
synthesised strand. This 
process is repeated 35-
40 times to amplify the 
piece of DNA between 
the forward and reverse 
primer sequences  
1 72 °C 10 minutes Further elongation 
1 10 °C ∞ Preservation 
Table 11: PCR programme for DLK1 gene product  
Table showing the PCR programme used. DLK1 primers for the 5 exons of the molecule were constructed and 
used for the reaction.  
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Primer Tm (°C) Annealing  
Temperature 
(°C) 
Sequence Product 
Length (bp) 
Human DLK1 
Exon 1 F 
59 62 AAGTGTTTCGGTGTTCCTGC 900 
Human DLK1 
Exon 1 R 
59 62 CCTCTGGCGCCACTTCTG  
Human DLK1 
Exon 2 F 
59 59 GCTGTTGGTGCCCTCGAG 385 
Human DLK1 
Exon 2 R 
59 59 CTCGCCCCACCAGTTTTCT  
Human DLK1 
Exon 3 F 
62 62 TCAGGTGGCTGGTGGTACT 511 
Human DLK1 
Exon 3 R 
64.8 62 CGGCCCAGCTGTATGTGTAT  
Human DLK1 
Exon 4 F 
62 62 AGGGAATCTCAGCTAGGCCAC 657 
Human DLK1 
Exon 4 R 
62.2 62 GACTGTCACTCACACGCATC  
Human DLK1 
Exon 5 F 
59 62 GTTGTAGCCTAGCCCCTGAG 972 
Human DLK1 
Exon 5 R 
59 62 CCGCGTATAGTAAGCTCTGC  
Table 12: DLK1 primers used for PCR reaction  
Table showing the nucleotide sequence for the 5 primers. Both forward (F) and reverse (R) primers are shown.  
2.3.3 Gel Electrophoresis 
After the DNA has been amplified, samples were combined with 5μl of loading dye (Fermentas) and 
run on a 1% agarose gel. The loading dye adds weight to the DNA to contain it within the wells of the 
gel. Higher molecular weights are separated more easily on lower percentage gels. The gel, 
containing GelRed ™ Nucleic Acid Gel Stain (1:20 dilution), was placed in an electrophoresis chamber 
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containing 1X TAE buffer (Tris-acetate-EDTA buffer; National Diagnostics), and an electrical current 
passed through it. DNA was visualised using a transilluminator. 
2.3.4 DNA Gel Extraction 
Gel extraction was carried out using Qiaquick® Gel extraction Kit from Qiagen. DNA fragments were 
excised from the agarose gel using a clean sharp scalpel. The gel slices were then weighed in a falcon 
tube. 3 volumes of buffer QG, a buffer containing a pH indicator allowing easy determination of the 
optimal pH for DNA binding, to 1 volume of gel was added to the gel strips. This was then incubated 
at 50°C for 10 minutes.  A Qiaquick spin column was placed into a collection tube after which the 
mixture was added to the column, 750 µl at a time, to bind DNA after which the mixture is spun in a 
centrifuge for 1 minute and the flow-through discarded.  Nucleic acids adsorb to the silica 
membrane in the high salt conditions provided by the buffer. A further 500 µl of buffer QG was 
added to the spin column and the sample centrifuged once more for 1 minute. 750 µl of Buffer PE 
(after addition of ethanol) is then used to wash the mixture. The sample was then left to stand for 
five minutes before spinning in a centrifuge for 1 minute. The spin column provided was centrifuged 
one more time at a speed of 13000rpm for 1 minute to get rid of excess wash buffer. The column 
was then placed into a new 1.5ml microcentrifuge tube. To elute DNA, 30 µl of buffer EB (10 mM 
Tris·Cl, pH 8.5) was added to the Qiaquick membrane and the sample allowed to stand at room 
temperature for 1 minute prior to centrifugation for 1 minute. The purified DNA was then analysed 
on a gel prior to sending the DNA samples to the Genome Centre for sequencing.  
2.4 DLK1 protein expression in placentas  
2.4.1 Protein extraction for Western blotting to detect DLK1 in placental 
tissue  
Placental biopsy samples were dissected on ice to prevent degradation by proteases. The tissue was 
then placed in an Eppendorf tube. 300μL of cold lysis buffer (Sigma-Aldrich) was added to a 5mg 
piece of placental tissue followed by homogenisation of the mixture. Subsequent to 
homogenisation, the solution was then placed in a cold centrifuge (4°C) for 20 minutes at 12,000 
rpm. The tubes were then removed from the centrifuge and placed on ice. Supernatant was 
collected and added to an equal volume of 2x Laemmli buffer (Sigma-Aldrich), containing SDS and β-
ME, then boiled for 10 minutes to denature proteins prior to gel loading. 
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2.4.2 Western blotting 
A pre-cast gel (SDS PAGE precast NuPage ®BisTris gels 4-12%, 10% or 12%) (Invitrogen) was briefly 
rinsed with distilled water and inserted into the gel tank. The tank was filled with 1x MOPS running 
buffer (50x 3-(N-morpholino)propanesulfonic acid (50nM MOPS, 50nM Tris Base, 0.1% SDS, 1mM 
EDTA pH 7.7)) to cover the gel and the comb removed. The protein ladder (Kaleidoscope pre-stained 
Protein Marker (Biorad) was loaded into the first well of the gel (10 μl for 10 well gel, 8 μl for 15 well 
gels). Samples prepared in 2x Laemmli buffer were centrifuged for 1 minute at 13 000 rpm and 
loaded into adjacent wells, typically between 10-20 μl, depending on the protein content of the 
lysate. The gel was run for one hour at 120V to begin with prior to increasing voltage to a maximum 
of 160V.  
 
2.4.3 Semi-dry transfer of proteins from gel to membrane 
A square segment of 0.1 μm pore nitrocellulose membrane was cut to the dimensions of the gel 
using extra thick filter paper (Biorad) as a template. The membrane was soaked in transfer buffer 
(0.9% glycine (w/v), 0.242% Tris (w/v), 20% methanol (v/v)) for 10 minutes prior to the transfer 
procedure. A sandwich of filter paper-membrane-gel-filter paper was assembled in the transfer cell. 
First, filter paper was briefly soaked in transfer buffer and placed on the transfer cell, pressed with a 
roller to remove excess buffer. Next the membrane was placed on top of the filter paper and then 
the gel was soaked and placed on top of the membrane.  Bubbles were removed by gently pressing 
the gel from the centre outwards. Finally the second filter paper was soaked and placed on top of 
the gel. The sandwich was pressed again with the roller to remove excess buffer. The transfer cell 
(Trans-Blot SD semi-dry transfer cell) (Biorad) was set to 15V for 40 minutes for one blot or 50 
minutes for two blots. After transfer the gel was discarded and the membrane subjected to 
Ponceau-S staining to determine the efficiency of the transfer.  
2.4.4 Ponceau-S staining 
Ponceau-S (0.2% Ponceau-S and 1% acetic acid) (Sigma-Aldrich) is a dye that reversibly stains protein 
bands without any adverse effects on the proteins. Staining membranes with Ponceau-S reveals any 
regions where the transfer has failed (seen as bubbles) as well as the amount of protein loaded per 
lane and the efficiency of the transfer. Membranes were placed in small containers, covered with 
Ponceau-S and left on a shaker for about two minutes. Ponceau-S was removed and the membrane 
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washed with PBS-tween (1x PBS +0.1% (v/v) Tween20) (Sigma-Aldrich). After one wash, protein 
bands became visible, and Ponceau-S staining was then removed with further washes in PBS-tween.  
2.4.5 Immunoblotting 
A blocking buffer was prepared by dissolving 5% non-fat dried powdered milk (Asda) in PBS-tween 
(0.1%), and mixing by inversion. Nitrocellulose membranes were transferred to 50 ml falcon tubes 
with 10 ml blocking buffer for one hour to prevent non-specific binding of the antibody. Tubes were 
rotated on a roller. After blocking, membranes were incubated in milk containing relevant dilutions 
of primary antibodies (Table 2) overnight at 4oC. 
The following day, membranes were subjected to 3x 10 minute washes in PBS-tween, incubated in 
milk containing fluorophore-conjugated secondary antibodies (Table 11) (goat anti-rabbit 800 
1:5000, goat anti-mouse 680 1:20 000) (Odyssey) for one hour and wash steps were repeated. Bands 
were detected using an Odyssey scanner at wavelengths 800 and 680.   
Table 2 Antibodies used for western blotting 
Ab Antigen/Fluorophore Species Company Dilution
1° 
 α-tubulin Mouse monoclonal Sigma-Aldrich (T6199) 1 in 10 000
1° DLK1 Rabbit monoclonal Abcam (ab 110636) 1 in 200
2° IRDye®680LT Goat anti-mouse Li-cor (925-68020) 1 in 20 000
2° IRDye®800CW Goat anti-rabbit Li-cor (925-32211) 1 in 5000
Table 13: Primary and secondary antibodies used for western blot experiments  
Table showing primary and secondary antibodies used for western blot experiments 
2.3 Data Analysis 
Multiple regression analysis was used to determine the significant independent contributors in the 
prediction of birth weight, femoral length, abdominal circumference, BPD respectively and maternal 
serum DLK1, maternal weight, maternal age, parity and ethnic origin [Caucasian, Afro-Caribbean, 
South Asian (Indian, Pakistani, Bangladeshi), Far East Asian (Chinese and the Orient), South East 
Asian (Philippines, Malaysia), Mixed]. The association between maternal serum DLK1 and the 
incidence of IUGR was assesses by comparing the relative risk at DLK1 levels below the 5th centile, at 
four different time points in pregnancy. Odds ratios (OR) for IUGR were calculated. Multiple 
regression analysis was further used to determine the independent contributors in the prediction of 
estimated fetal weight from the following variables: maternal serum DLK1, maternal age, maternal 
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weight, smoking status, parity) in the second and third trimester, in the Finnish cohort. Significance 
of Statistical significance was determined by 1-way analysis and 2-way analysis of variance 
(Friedman ANOVA).  A p value under 0.05 (p<0.05) was taken as statistically significant. This was 
used to analyse the statistical difference between the IUGR and normal pregnancy DLK1 levels 
within the Finnish cohort and in addition the statistical difference in DLK1 levels in normal compared 
to abnormal placental histology findings in the RLH cohort. Multiple correlation analysis was run to 
compare DLK1 serum levels with placental parameters. Statistical analysis was performed with SPSS 
Statistics for MAC (v. 24, IBM), Microsoft Excel for MAC and GraphPad PRISM for MAC (v.7, Software 
MacKiev) software 
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Chapter 3 Results: Serum DLK1 levels during pregnancy 
3.1 Aims of study 
DLK1 has been shown to be present in human embryonic tissue 138and reduced levels as seen in 
animal knockout models119 and human Temple syndrome123result in IUGR. In addition, DLK1 levels 
have been shown to be reduced in IUGR in humans when compared to normal pregnancies143. With 
this in mind, my aims and objectives include: 
• To investigate whether maternal serum DLK1 can be predictive of fetal growth parameters 
such as abdominal circumference, bipareital diameter and femoral length at four time 
points in pregnancy.  
• To investigate the gestation at which DLK1 can be predictive of birth weight and moreover 
assess the relationship between DLK1 and estimated fetal weight during pregnancy.  
• To assess whether maternal serum DLK1 levels can be used to evaluate the relative risk for 
IUGR. In this way I aim to ascertain the important period of action for DLK1 and therefore 
establish a rationale for interpreting maternal DLK1 levels depending on timing of sampling, 
as a biomarker for intrauterine growth. 
3.2. DLK1 levels during pregnancy compared to fetal growth parameters 
In the first instance, DLK1 levels were measured in serum by ELISA as detailed in chapter 2. These 
results showed a steady rise in concentrations during gestation with a sharp fall after delivery 
(Figure 15).  This is in keeping with previous studies in both humans138and animals 139. Serum DLK1 
levels were then compared to in utero growth parameters. A multiple regression analysis was 
carried out to predict birth weight and fetal growth parameters based on DLK1 levels(Table 12). 
Additional variables taken into account include maternal age and weight at booking, ethnicity and 
parity. Serum DLK1 levels at four time points were taken into consideration and compared to birth 
weight and in addition fetal growth parameters measured at the same time as the sampling. Fetal 
growth parameters considered included femoral length (FL), abdominal circumference (AC) and 
bipareital diameter (BPD).  Serum DLK1 levels taken at 32-34 weeks gestation were found to be 
highly significant of birth weight and abdominal circumference (F = 19.905, P <0.0001) and F = 
17.252, P<0.0001) respectively. In addition serum levels at 26 weeks gestation were also predictive 
of birth weight and in addition of femoral length (F = 5.902, P = 0.02 at 26 – 28 weeks; F = 6.495, P = 
0.017 at 32-34 weeks). DLK1 was not predictive of BPD at any gestation
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Further analysis was carried out to assess relative risk of IUGR when maternal serum DLK1 levels 
were low. Analysis of all maternal serum DLK1 levels was carried out and serum levels in the 5th and 
10th percentile were used as a cut off for low DLK1 levels (Table 13). This was run for all four-time 
points but however samples from 26 – 29 weeks gestation were found to be predictive of IUGR. 
Using the 5th percentile as a cut off (9.69 nag/l) revealed OR 14.7(95% CI 3.85  - 55.2). The CI 
(Confidence interval) is wide but this is likely de to the small sample size. These results would 
therefore need to be confirmed in a larger cohort with a larger proportion of IUGR pregnancies. 
They however highlight the potential for maternal serum DLK1 levels as biomarkers for IUGR. 
Figure 17: Maternal serum DLK1 levels during pregnancy  
Graph showing maternal serum DLK1 levels taken at four time points during pregnancy with a further sample 
taken after delivery. Levels rise particularly between the 28th and 34th week of pregnancy.  Samples taken 24 – 
48 hours after delivery show a drop in DLK1 to pre pregnancy levels. Post delivery levels are depicted by the 
red arrows. The earliest post delivery sample obtained was at 37 weeks (first arrow).   
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Gestation in 
weeks 
Statistical 
Analysis 
Birth weight 
SDS 
Femoral 
length 
Abdominal 
circumference 
Biparietal 
diameter 
18 – 21 
 
R2 
F ratio  
P value 
0.154
0.633 
0.433 
0.267
1.989 
0.17 
0.002
0.095 
0.822 
0.131 
0.096 (0.983) 
0.747 
27 – 29 
 
R2 
F ratio  
P value 
0.147
4.642 
0.04 
0.179
5.902 
0.02 
0.073
2.118 
0.157 
0.506 (2.84)
2.06 (0.118) 
0.203 
32 – 34 
 
R2 
F ratio  
P value 
0.424
19.905 
<0.0001 
0.440
6.495 
0.017 
0.390 
17.252 
<0.0001 
0.512 
2.13(0.108) 
0.95 
37 – 39 
 
R 
F ratio  
P value 
0.175
4.867 
0.038 
0.370
3.644 
0.069 
0.242
1.936 
0.243 
0.559 (3.37)
2.28 (0.97) 
0.06 
Table 14: Predictability of DLK1 for birth weight and other fetal growth parameters.  
Multiple regression analysis run to compare DLK1 serum levels taken at four times points in pregnancy to 
different fetal growth parameters and birth weight. Maternal age, weight, parity and ethnicity were included 
and they were shown not to be predictors of the fetal growth parameters or birth weight. Significant P values 
are shown in bold. These results are from the RLH cohort.  
 
DLK1 cut off Gestational age in weeks OR (95% CI) 
5th centile 26 – 28 14.5 (3.81 – 55.2) 
10th centile 26 – 28 4.5 (0.56 – 36.133) 
Table 15: Relative risk for intrauterine growth restriction based on maternal serum DLK1 levels  
Table showing relative risk, shown as odds ratio of developing IUGR with DLK1 levels in the 5th centile or 
below or for DLK1 levels in the 10th centile and below, at between 26 to 28 weeks gestation. Confidence 
intervals are shown in brackets.  OR – Odds ratio 
3.2.3 Finnish Data 
In the first instance the DLK1 ELISA was carried out as described in the previous chapter. We see 
from Figure 16 that there is a significant difference in serum levels between IUGR and AGA 
pregnancies in the third trimester. This is seen with both birth length and birth weight. The 
difference between the two groups was not significant in the second trimester (Table 14). 
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Demographics of the two groups are shown in table 14. There was no significant difference in most 
of the two groups’ demographics. Interestingly there was a significant difference in gestational age 
at birth. This is likely because in most cases of severe IUGR neonates will be delivered early to avoid 
further complications. There was a highly significant difference seen in BW and BL between the two 
groups.  
A multiple correlation analysis was carried out to assess whether DLK1 is an independent variable 
when levels were compared to EFW. The analysis was carried out both in the second and third 
trimester. Variables such as maternal age, weight, smoking status and parity were taken into 
consideration when running the analysis. We see that there are significant R-values for both 
trimesters suggesting that DLK1 levels taken during pregnancy can predict EFW. The other variables 
(maternal age, weight, smoking status and parity) were found not to have an effect on EFW.  
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Normal IUGR  
Gestation in 
weeks  
Mean 
(Range) 
DLK1 levels ng/ml 
 
 
Range                Mean ± SD 
Gestation in 
weeks  
Median 
(Range) 
DLK1 levels ng/ml
 
 
Range                Mean ± SD 
P value 
Trimester 2 
19.82 (15.3 
– 23.9)  
N = 9 
 3.93 – 
30.73 
8.36 ±8.65  
21.66 (19.1 
– 23.9) 
N = 5 
1.99 – 
20.81 
9.34 P = 0.9 
Trimester 3 
30.97 (23 – 
40.1) 
N = 47 
5.87 – 
107.6 
35.5± 22.36 30.99 (24.9 
– 38.3) 
N = 16 
 
9.05 – 
62.07 
21.61 ± 
12.73 
P = 0.0113 
** 
Table 16: DLK1 levels in normal compared to IUGR pregnancies in the Finnish  
Analysis of DLK1 levels in normal and IUGR pregnancies in both the second and third trimester within the 
Finnish cohort. There is a significant difference between the two groups in the third trimester (p values in bold) 
but not in the second. IUGR - intrauterine growth restriction.  
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3.2.7 DLK1 and IUGR 
 
Figure 18:  Birth length and birth weight with serum DLK1 levels in IUGR compared to normal pregnancies  
Comparisons are made with both birth weight (top graph) and birth length (bottom). There is a significant 
difference in DLK1 levels between the IUGR and normal pregnancy groups. BL – birth length; BW – birth 
weight. Results from the Finnish cohort
Normal IUGR( BW SDS < -2)0
100
200
300
DL
K1
 ng
/m
l
Maternal serum DLK1 levels in IUGR 
compared to normal pregnancies
P = 0.0113 *
Normal IUGR ( BL SDS < -2)0
100
200
300
DL
K1
 ng
/m
l
Maternal serum DLK1 levels in IUGR 
compared to normal pregnancies 
P = 0.0249*
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Characteristics IUGR  
N = 19 
       Normal  
N = 50 
P value 
Age, yrs.  31.26 
() 
31.09 (18.95 - 40.91) 0.91 
BMI 25.81 (19.38 – 36.05) 23.37 (18.14 - 38.48) 0.12 
Gravidity 2 (1-7) 2.86 (1 - 13) 0.1 
Gestational age at 
delivery 
35.88 (25.1 – 41.1) 37.38 (24.7 - 42.1) 0.03 * 
Birth weight (grams) 2031 (550 – 3370) 3113 (690 - 4750) < 0.0001 **** 
Birth weight SDS -2.55 (-4.8 - -0.9) -0.162 (-1.7 - 1.9)  
Birth length 42.62 (30 – 48) 47.85 (31 - 54) < 0.0001 **** 
Birth length SDS -2.96 (-4.9 - -1.5) -0.18 (-1.7 - 2.3)  
Female neonate 7 (37%) 25 (50%) > 0.9999 
Male neonate 12 (63%) 25 (50%) > 0.9999 
Table 17: Characteristics of IUGR compared to normal birth weight neonates in the Finnish cohort  
Comparison of demographics of the IUGR and Normal groups. Apart from a significant difference in size and a 
difference in gestational age at birth   there was no other significant difference in the characteristics between 
the IUGR and the normal pregnancy groups. The median is shown with the range in brackets/ number and 
percentage in brackets as appropriate. This data is from the Finnish cohort  
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3.2.8 Maternal serum DLK1 levels compared to Estimated Fetal Weight 
Variable Second trimester N = 10 Third trimester N = 34 
DLK1 
R2  (95% CI)  
P value 
 
0.7161 (0.46 – 0.96) 
0.002** 
 
0.45 (0.43 – 0.82) 
<0.0001**** 
Maternal age 
R2 (95% CI) 
P value 
 
0.01813 (-0.70 – 0.54) 
0.7108 
 
0.0849 (-0.57 – 0.05) 
0.0945 
Maternal weight 
R2 (95% CI) 
P value 
 
0.124 (-0.36 – 0.8) 
0.3182 
 
0.0637 (-0.10 – 0.54) 
0.1565 
Maternal Smoking Status 
R2 (95% CI) 
P value 
 
0.0012 (-0.65 – 0.61) 
0.9243 
 
 
Table 18: Correlation between DLK1 levels and estimated fetal weight in the second and third trimester 
within the Finnish cohort.  
Table showing the result of a multiple correlation analysis. A significant correlation is seen when maternal 
serum DLK1 levels in the second and third trimester are compared to estimated fetal weight. There is no 
significant correlation between estimated fetal weight and maternal age, weight or smoking status. Of note 
there were no smokers in the third trimester 
3.3 Discussion 
These studies confirm previous knowledge about maternal serum DLK1 levels in pregnancy. I show 
further that there is a relationship between fetal growth parameters and maternal serum DLK1 
levels, which is seen as an independent variable from as early as 26 weeks gestation onwards. In my 
aims I set out to explore whether DLK1 serum levels could give an indication of growth at specific 
time points in pregnancy. Importantly serum levels from 26 weeks gestation onwards can give an 
idea of the fetal growth trajectory and thereby identify at risk pregnancies. Interestingly maternal 
serums DLK1 Ievels taken at 32 to 34 weeks gestation are highly predictive of both birth weight and 
abdominal circumference. This is an important period for the fetus in utero as it is a time of rapid 
growth. During this period there is a rise in a number of placental hormones including insulin and 
leptin levels. DLK1 may interact with some of these placental hormones to effect its mode of action. 
DLK1 has been shown to stimulate an increase in insulin producing pancreatic β cells160 and this can 
be supported by the peak in insulin levels in late gestation which is similar to the timing of peak 
DLK1 levels in gestation. This time point in gestation may involve complex signal mechanisms and 
interplay between placental and fetal hormones in order to ensure sufficient nutrients for growth. 
DLK1 levels taken at this gestation can be used to assess the efficiency of this process and detect 
pathology.  
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Reduced femoral length can be seen in IUGR. In addition however the effects of DLK1 on 
endochondral ossification161 may contribute to the relationship between DLK1 serum levels and fetal 
femoral length. Further works including functional studies are required to clarify this proposed 
mechanism of action. I hypothesised that DLK1 would have a role in regulating long bone growth as 
seen by serial measurements of femoral length. This has been proven by the data. There is a 
significant regression (F5.902, P0.022) from as early as 26 weeks gestation. Serial results were useful 
in determining time points at which DLK1 effects would be most significant. DLK1 is likely to have 
tissue specific functions that vary depending on the gestational age.  
My final aim was to investigate whether DLK1 levels can be used to assess the risk of developing 
IUGR. Ideally a larger cohort is required to make such an assessment but in any case the result 
suggest the need for further investigation.  When the 5th centile for DLK1 levels at 26 weeks 
gestation is used as a cut off, RR for IUGR as 14.5 (95% CI, 3.8 – 55.2). This work provides important 
information about aspects of fetal growth that are likely to be regulated by DLK1. The significant 
difference seen in maternal DLK1 levels between IUGR and AGA pregnancies within the Finnish 
cohort confirms further that DLK1 has an important role to play in fetal growth. This larger cohort 
was important in elucidating the significant difference between the two groups. In addition, I was 
able to show with this cohort that DLK1 levels were also predictive of EFW. The limitations to using 
samples not collected prospectively however means that blood sampling was not always taken as 
the same time as other measures such as ultrasonography for instance, thereby leaving fewer results 
available for use when performing analysis. In addition unlike the RLH cohort, sampling was not 
always carried out at a similar gestation each time. There is a need for a larger study carried out 
prospectively, to allow further interrogation of DLK1 actions in utero. Below is a proposed 
mechanism for he actions of DLK1 (Figure 17). Other modes of actions are likely, especially via the 
placenta. DLK1 is likely to exert its effect either directly on the fetus or on the placenta, at different 
time points in pregnancy. I went on to carry out placenta studies, as the placenta is an important 
component of the feto-maternal unit.  
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Figure 19: Proposed mechanism for DLK1 mode of action  
Flow diagram showing factors influencing fetal growth and a proposed mechanism for DLK1 mode of action. 
GH – growth hormone. IGF2 – Insulin – like Growth Factor-2 
IGF2 
 
Normal glucose and amino acid 
availability 
Fetal Growth 
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Insulin 
 
? DLK1 
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Chapter 4 Results:  Placental studies 
4.1 Aims of study 
In the previous chapter I have shown that DLK1 plays an important role in fetal growth, especially in 
the third trimester.  To further evaluate the functions of DLK1, my aims are: 
• To assess the correlation of maternal DLK1 levels at various stages of pregnancy with the 
placental size and other placental parameters as these placental parameters are surrogate 
markers for placental function.   
• To investigate cells in the placenta that are likely to produce DLK1 by performing 
immunohistochemistry experiments. The trophoblast layer of cells in the human placenta 
contains receptors for a number of hormones including leptin, insulin and IGF. DLK1 
expression in the trophoblast layer of these cells may suggest a role in trophoblast invasion 
in addition to other regulatory functions in the placenta during pregnancy.  
• To assess whether DLK1 levels are associated with abnormal placental histology findings, 
particularly those suggestive of maternal vascular malperfusion of the vascular bed.  
4.2 Relationship between serum DLK1 levels and placental parameters 
 
Gestational Age 
(weeks) 
Placental 
weights 
Placental 
Volume 
Cord Diameter Feto: placental 
Ratio 
18 – 21  R = 0.92 
P = 0.67 
N = 24 
R = 0.24 
P =0.25 
N = 24 
R = -0.14 
P = 0.51 
N = 23 
R = 0.21 
P = 0.34 
N = 24 
26 - 29 R = 0.26 
P = 0.21 
N = 25 
R = 0.42 
P = 0.04 * 
N = 25 
R = -0.19 
P = 0.38 
N = 24 
R = -0.10 
P = 0.62 
N = 25 
32 – 34 R = 0.42 
P = 0.035 * 
N = 25 
R = 0.42 
P = 0.04 * 
N = 25 
R = -0.17 
P = 0.44 
N = 24 
R = -0.20 
P = 0.33 
N = 25 
37 - 39 R = 0.70 
P = 0.0006 *** 
N = 20 
R = 0.53 
P = 0.02 * 
N = 20 
R = -0.41 
P = 0.08 
N = 19 
R = -0.34 
P = 0.14 
N = 20 
Table 19: Comparison between DLK1 and placental parameters in the Royal London Hospital cohort  
Table comparing DLK1 maternal serum levels taken at 4 time points to placental weight, volume, cord 
diameter and feto: placental ratio. Significant p values are highlighted in bold.  
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To achieve my first aim, a correlation analyses were carried out to access whether there was a 
significant correlation between placental characteristics and maternal serum DLK1 levels. There was 
a positive correlation seen between maternal serum DLK1 levels and placental weights from 32 
weeks gestation onwards. This correlation was seen to be strongly significant (P = 0.0006) at 37 – 39 
weeks gestation. Further correlation was seen when serum DLK1 levels were compared to placental 
volume. There appears to be a correlation with DLK1 levels from 26 weeks gestation onwards. These 
findings suggest a role for DLK1 in regulating placental function. There was no correlation seen when 
either cord diameter or feto: placental ratio was compared to serum DLK1 levels (Table 16) 
4.3 Relationship between gross anatomy of placenta and DLK1 levels 
 
Table 
20: 
Comparison between DLK1 maternal serum levels at four time points and placental gross morphology  
There was no significant difference seen when DLK1 levels compared with cord position and either the 
absence or presence of thrombus, fibrosis or haematoma. 
 
A multiple regression analysis was carried out to assess whether there was a relationship between 
DLK1 levels at four time points during gestation and gross placental morphology. Cord insertion 
(central, marginal or peripheral), and the presence or absence of thrombus, fibrosis or haematoma 
was taken into consideration. There was no significant difference in the DLK1 levels when these 
variables were taken into consideration. In addition maternal age, parity and ethnicity were taken 
into consideration at each gestation and these were also found not to influence DLK1 levels and 
were therefore not confounding factors.  
Gestational 
Age 
(weeks) 
Analysis Cord 
insertion 
Thrombus Fibrosis Haematoma 
18 – 21 
 
R2 = 0.291  
F = 1.2 
N = 24 
P  = 0.7 
 
P = 0.877 P = 0.705 P = 0.287 
26 – 29 
 
R2 = 0.291 
F = 0.77 
N = 24 
P = 0.845 P = 0.129 P = 0.970 P = 0.822 
32-34 
 
R2 = 0.430  
F = 1.414 
N = 24 
P = 0.472 P = 0.247 P = 0.560 P = 0.134 
37-39 
 
R2 = 0.401  
F = 0.838 
N = 23 
P = 0.66 P = 0.227 P = 0.197 P = 0.686 
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4.2.1 Localisation of DLK1 expression in human placenta 
Having assessed the macroscopic appearance of the placenta, immunohistochemical studies were 
carried out, to fulfil my second aim. In the first instance, DLK1 immunostaining was carried out on 
placenta from our cohort as detailed in chapter 2. The results of this staining can be seen in figure 
18. DLK1 is seen as brown staining in the villi (panel B). Staining appears cytoplasmic in the 
trophoblast layer (black arrow) and dot-like in the fetal endothelial cells (red arrow). An H&E panel is 
shown for comparison (Panel A). CK7 staining is seen in panel C. CK 7 is a marker for trophoblast cells 
and confirms the trophoblast staining we see with DLK1. This suggests that DLK1 may have a role in 
regulating secretion of hormones, in addition to regulating other trophoblast functions such as 
invasion of the myometrium. Staining is shown in the EVT (Figure 19), which displays a pattern 
suggestive of DLK1 secretion by these cells. 
Western blot analysis carried out in Figures 19 shows the isolation of a 50-kDa protein, which is the 
soluble form of DLK1. This soluble isoform of DLK1 is likely the more abundant one in the placenta. 
This may explain some of the functions of DLK1. Further stimulation results possible with placental 
explants or cell lines may clarify this.  
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Figure 20: Immunohistochemistry panels showing DLK1 and CK7 positive cells  
Immunohistochemistry panels showing H& E panel of the villi (A); DLK1 positive cells are seen as the fetal 
endothelial cells and trophoblast (B); CK7 is seen as positive in trophoblasts,(C)  
 
 
 
 
 
Figure 21: Extravillous trophoblasts in normal (A) compared to IUGR placenta (B).  
This is from an IUGR placental decidua. Dot like staining is seen in the cytoplasm – black arrow. Dot like 
staining is seen in the cytoplasm (green arrow) with some membrane staining (black arrow). 
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Figure 22: DLK1 protein expression in the placenta  
DLK1 shown here as a 50kDa protein.  Mouse pituitary lysates were used as a positive control.
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4.2.2 Intensity of DLK1 immunostaining in comparison to serum levels 
Following the initial immunostaining with DLK1, comparisons were made between the intensity of 
staining in the different cell compartments and maternal serum DLK1 levels, as described in the 
methods section. There was however no significant difference seen when serum DLK1 levels were 
compared to intensity of staining.  Analysis was carried out using one-way ANOVA. 
Further comparisons were made between intensity of staining in fetal endothelial cells as compared 
to trophoblast cells (Figure 20). Here we see that there is a significant difference in the intensity of 
staining seen in the two groups of cells. Overall fetal endothelial cells are seen to exhibit a higher 
intensity of staining. This may provide a clue to the source of DLK1 being the fetus. Studies have 
shown that certainly in mice, the source of Dlk1 is the fetus143. Further studies are required on 
human placenta however as the mouse placenta is different morphologically and may therefore 
differ in function. 
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Figure 23: Staining of DLK1 in fetal endothelial cells compared to trophoblasts  
Graph showing a comparison in DLK1 intensity between fetal endothelial and trophoblast cells. A significant 
difference is seen in the intensity of staining between the two cell types.  
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4.2.3 Comparison of histomorphometric findings to serum DLK1 levels 
To fulfil my final aim, set criteria were used to review H&E slides of the placenta as described in the 
methods section. After reviewing the histology, findings were compared to DLK1 levels at four 
different time points. There was no significant difference in DLK1 levels in cases of abnormal villous 
maturation or signs of inflammation. When findings were compared in cases where clusters of 
MTGC were seen compared to the normal decidua, at 18-21 weeks there was a significant difference 
in DLK1 levels between the two groups (P = 0.0051). A further significant difference is seen at 31-35 
weeks gestation (P = 0.0191). There was no significant difference seen in serum levels at either 26-
29 weeks or 37-39 weeks gestation.  
These suggest that DLK1 has an important function to play in trophoblastic invasion. Other 
abnormalities of placental bed malperfusion were seen in one of the case with sever IUGR (BD SWS -
3.3) and low DLK1 levels all through gestation. There were findings of avascular villi with accelerated 
maturation. A larger IUGR cohort would allow for evaluation of the predictability of DLK1 in cases of 
poor placentation/ trophoblastic invasion. 
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Figure 24: Comparison of DLK1 serum levels in cases of MTGC compared with normal maternal decidua  
Graphs showing comparisons of maternal serum DLK1 levels between participants exhibiting MTGC in the 
decidua and those in which MTGC are absent. A significant difference is seen at 18-21 weeks and 31-35 weeks. 
MTGC – multinucleated trophoblastic giant cells.  
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4.3 Discussion 
The placenta comprises different 3D spaces (cells, syncytium, vascular and extracellular spaces) 
whose volume reflects compartmentalisation of function at different levels of organisation162. From 
the results we can see in the first instance that maternal serum DLK1 levels in late gestation 
correlate both with placental weight and volume. The correlation seen between DLK1 levels at 37-39 
weeks gestation and placental weight is particularly strong. Placental weight is known to relate to 
fetal growth with maternal nutrition being one of the factors known to influence placental weight. In 
my work this correlation is only seen with DLK1 serum levels taken from 37 weeks gestation 
onwards. Serum levels taken at this gestation can be used to predict placental function in nutrient 
transfer. We know that nutrient transfer capacity of the placenta depends on its size, morphology, 
blood flow and availability of nutrient transporters2. Despite the close correlation known between 
placental size and fetal growth, the mediation of the effect of placental weight on associations 
between prenatal factors is only partial. The pattern of fetal growth is a major determinant of the 
subsequent health of the infant. Sferruzi-Peri et al have showed that in undernourished mice fetal 
growth is maintained until late pregnancy, despite reduced placental weight, through adaptive up-
regulation of placental nutrient transfer163. In my work correlation is seen between serum DLK1 
levels from 26 weeks gestation onwards and placental volume. This would suggest a further 
influence of DLK1 on placental function. Animal studies have shown cases of placental hypoplasia in 
cases of mUPD12 164. DLK1 is likely to promote villi growth and development, which may be reflected 
in the placental volume. In addition DLK1 serum levels were found to be associated with fetal 
growth (EFW) and birth weight in the previous chapter. This effect is most likely due to the influence 
of DLK1 on placental function. DLK1 may have a role to play in the functioning of nutrient 
transporters, in addition to other modes on action during gestation. Due to the association of DLK1 
serum levels early in gestation with placental volume and not weight until late gestation, DLK1 may 
have a role to play in some of the adaptive responses of the placenta in optimising nutrient delivery 
to the fetus. Placental weight is but one of several physical parameters that may predict outcomes, 
including placental thickness, width, length and cord placement position. These parameters are 
shown in the appendix. 
 
My immunohistochemistry studies showed DLK1 staining in fetal endothelial and trophoblast cells. 
The staining in the fetal endothelial cells appears to be more intense when compared to that in 
trophoblast cells. This may mean, as previously suggested by Floridon et al138, that the source of 
DLK1 is the fetus and that DLK1 is transported from the fetal endothelial cells to the trophoblasts , 
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via the polarised membrane (BM) as above prior to entering the maternal circulation via the MVM. 
Further experiments including In Situ hybridisation studies are required in order to ascertain mRNA 
expression of DLK1.  
 
From the histological studies we see that a strongly significant difference was seen when serum 
DLK1 levels at 18-21 weeks were taken into consideration in comparing cases in which MTGC were 
seen as opposed to those with normal extravillous trophoblasts in the maternal decidua. MTGC are 
seen at the site of implantation in the myometrium as a normal occurrence, in early gestation165. 
They are fused extravillous trophoblast cells that have lost the ability to invade. MTGC presence is 
inversely related to gestation with numbers peaking at the turn of the second and third trimester 
with a decline in numbers after that. The presence of MTGC at term is associated with abnormal 
implantation and poor placental perfusion. These results would imply that a serum DLK1 level taken 
as early as 18 weeks gestation can give an indication of how efficient the process of implantation has 
been in addition to elucidating the effectiveness of placental perfusion. DLK1 may have a role to play 
in the invasive processes seen during placentation and may influence placental perfusion and 
ultimately fetal growth. Placental insufficiency was a feature in all our cases of IUGR as detected by 
Doppler studies antenatally.  
 
DLK1 may therefore play a role in the process of implantation with serum levels at 18 weeks 
gestation being able to give an indication as to whether invasion of the myometrium is appropriate 
or shallow, resulting in poor placental function ,by regulating signalling pathways involved in 
trophoblast invasion. Furthermore, in view of the correlation seen with placental weight and 
volume, there is likely to be a further role in nutrient transport within the placenta later in gestation. 
Finally from the previous chapter we see an association between DLK1 levels and FL suggesting a 
role for DLK1 in longitudinal growth. These functions need to be explored with further experiments 
including functional studies and In Situ hybridisation. We can however begin to appreciate that the 
effects of DLK1 in utero are far reaching and therefore measuring circulating levels of this protein 
can provide us with information about the intrauterine conditions, depending on timing of the 
samplings. Further studies required are discussed in the next chapter.  
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Chapter 5: General Discussion
5.1 DLK1 levels rise in late gestation
I embarked on this work to demonstrate that DLK1 has an important role to play in intrauterine 
growth and development in man, and that this role may vary depending on the stage of pregnancy. 
In late gestation, the rise in DLK1 levels is also seen to coincide with a time for rapid growth for the 
fetus. It appears that DLK1 has functions both in early and late gestation. Early gestation functions 
appear to focus on placentation whilst in late gestation; DLK1 may regulate nutrient transport and in 
addition interact with placental hormones to allow for adaptation at this gestation. Although DLK1 
levels were found to be undetectable before 17 weeks gestation138, serum levels may not be 
completely reflective of amounts being secreted by the fetus and or placenta. It would be useful to 
measure urine levels at this stage and calculate creatinine clearance of DLK1 in order to better 
understand its function in early gestation. Renal clearance tends to increase in early gestation as an 
adaptive process to the changes occurring to the vasculature and increased circulating volume of 
blood. Creatinine clearance would therefore give us a more accurate measure of DLK1 
concentration.
5.2 DLK1 regulates femoral length and abdominal circumference 
growth particularly in late gestation
I have shown a relationship between DLK1 and fetal growth parameters, specifically abdominal 
circumference and femoral length. In chapter 3 we saw that there was an association between DLK1 
serum levels and FL from as early as 26 weeks gestation. Floridon et al have shown that a small 
number of resting chondrocytes within epiphyseal discs of the human embryo remain positive for 
DLK1 throughout gestation when immunohistochemistry studies were carried out138. We know that 
the epiphyses of long bones are an important site of endochondral ossification where a cartilage cast 
is invaded by mesenchymal progenitors, which leads to the appearance of a chondrocyte-enriched 
growth plate that allows for longitudinal bone growth. The secreted DLK1 may have a role in 
osteogenesis via the MAPK pathway whilst the membrane bound DLK1 may have a direct influence 
on ossification. Both processes result in the growth of long bones, of which the femur is an example, 
and may explain the positive correlation seen between serum DLK1 levels and FL. Knockout studies 
in animals have shown skeletal abnormalities in Dlk1 null mice further supporting a role for DLK1 in 
skeletal development119. In addition patients with TS are seen to have abnormal skeletal 
development. Phenotypes of TS described, which suggest abnormal musculoskeletal development, 
include scoliosis, small hands, frontal bossing with a broad forehead and hyperextensible joints124. 
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These patients have also been described as having delayed motor milestones particularly walking 
which may however also be influenced by muscle weakness rather than solely by skeletal 
development. This may mean that in cases where DLK1 levels are low during pregnancy, the 
resulting neonates may require follow up to ensure normal bone health as we know that apart from 
locomotion and organ protection, skeletal functions include glucose and adipose metabolism in 
addition to phosphate renal clearance and maintenance of the haematopoietic niche. In addition a 
better understanding of DLK1 mechanisms of action may help prevent potential skeletal 
abnormalities in pregnancies identified to have low DLK1 levels.  
The significant correlation seen between maternal serum DLK1 levels and abdominal circumference 
from 32 weeks gestation onwards is likely to be reflective of placental adaptations in late gestation. 
As mentioned previously in chapter 1, placental growth slows during the last half of gestation but 
the placenta adapts in order to provide for the growing fetus. One of the ways in which the placenta 
adapts is by a change in morphology. It is likely that nutrient transporters, particularly GLUT1, are up 
regulated by DLK1 leading to an increase in abdominal circumference. In addition, serum levels of 
one of the placental hormones, leptin, is seen to rise during gestation with a peak in late second to 
early third trimester, thereby remaining stable until labour166. We can see from our results, in 
chapter 3, that the correlation between abdominal circumference and DLK1 is highly significant (P  = 
0.0004) at 32-34 weeks, compared to 37-39 weeks (P  = 0.025). The earlier gestation probably 
corresponds to the leptin peak. DLK1 is likely to have a role in regulating leptin secretion by the 
placenta in order to optimise fetal growth in mid to late gestation. The protein has been shown to 
regulate leptin secretion in adipocytes cells110 and may therefore regulate placental leptin. This 
proposed mechanism of action requires further work with respect to functional studies. Neonates 
born as a result of IUGR particularly if secondary to placental insufficiency are seen to have reduced 
abdominal circumferences. An appreciation of the relationship between DLK1 and abdominal 
circumference, which is likely to involve leptin, may allow a reduction in some of the complications 
seen in neonates with IUGR. Abdominal circumference is seen as the most sensitive measure of fetal 
growth and this correlation with DLK1 may signify the overall influence of DLK1 on fetal growth, 
making it a potential biomarker for IUGR.
5.3 DLK1 is predictive of birth weight from 26 weeks gestation onwards
I have in addition shown that DLK1 can predict birth weight from 26 weeks gestation onwards from 
multiple regression analyses. DLK1 is likely to exert its effect directly, on the growing fetus, in 
addition to indirectly, through actions on the placenta (Figure 22). The impact of DLK1 on fetal 
growth is likely to be secondary to interplay between a numbers of factors. The effects of DLK1 are 
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likely to vary through gestation as the rate of growth and the needs of the fetus fluctuate.  Further 
studies including immunohistochemical experiments with co-localisation within the placenta of DLK1 
and other placental hormones will offer an explanation for the changes seen in the various fetal 
growth parameters in relation to DLK1 maternal serum levels.  
5.4 DLK1 regulates placental function
I then went on to carry out placental studies, which have also yielded interesting results. We know 
from animal knock out studies that the Dlk1 null mice are seen to have abnormal placentas, which 
are hypoplastic and also exhibit abnormal vasculature. In the first instance we saw a correlation 
between maternal serum DLK1 levels from 32 weeks gestation onwards and placental weight at 
term. This correlation from 32 weeks gestation onwards is also likely to be secondary to adaptive 
changes by the placenta as described above, such as an up regulation of nutrient transporters. 
Glucose is the principle energy substrate for the placenta and fetus.  Placenta glucose transport is 
mediated primarily by GLUT1, found at both the intervillous space facing MVM and at the fetal 
facing BM and by GLUT3 found on the MVM only. It would be useful to look at the distribution of 
nutrient transporters at different stages during gestation and compare this to maternal serum DLK1 
levels. DLK1 may affect nutrient transport by directly binding to the transporters or may produce 
posttranscriptional changes thus influencing the function of nutrient transporters in that way. There 
appears to be a highly significant correlation between maternal serum DLK1 serum levels from 37 
weeks gestation onwards and placental weight, supporting the suggestion that DLK1 has a role in the 
functioning of the placenta. The difficulties of obtaining human placenta before term makes looking 
at the direct influence of maternal serum DLK1 on placental weight at earlier gestations challenging. 
Our initial results however suggest conceptions for further avenues of investigation. In addition if 
DLK1 levels are seen to be low, it may trigger further assessment of the placenta for example 
Doppler flow measurements to access placental efficiency. Maternal serum levels would identify 
those pregnancies that may need closer surveillance. Furthermore, we have shown a positive 
correlation between maternal serum DLK1 levels and placental volume at term. This correlation is 
seen with maternal serum levels from as early as 26 weeks gestation. This earlier correlation 
compared to that seen with placental weight suggests that other physical parameters of the 
placenta other than weight can predict function. The placenta volume is reflective of the surface 
area of the placenta, which is important for the function of trophoblasts in the villi. In addition the 
depth of the placenta for instance can provide evidence of the efficiency of implantation and 
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development of placental vasculature. It would be useful to carry out further studies with serial 
placental volume estimation by ultrasonography.  
5.5 DLK1 is secreted by fetal endothelial and extravillous trophoblastic 
cells
Immunohistochemistry studies revealed DLK1 staining in a secretory population of placental cells. In 
addition, demonstration of the protein in the placenta via western blots further confirms the 
presence of DLK1 in these tissues. The identification of the protein as a 50-kDa protein suggests that 
the DLK1 found in maternal serum is the soluble isoform. The dot-like staining seen suggests 
secretion and extracellular transport of DLK1 by the fetal endothelial cells and EVT. In addition, the 
cytoplasmic staining seen may suggest posttranslational influences by DLK1 in trophoblast cells. 
There is a flow of substances from the fetus (fetal endothelial cells) through the BM on the ST and 
MVM before being transported into the maternal circulation, which is in direct contact with the 
MVM. The converse is true with transport of substances occurring from the maternal circulation to 
the fetus. The staining seen in the EVT also suggests that these cells are involved in secretion and 
extracellular transport of DLK1. DLK1 may have a role to play in trophoblast invasion.
5.6 Low DLK1 levels are associated with signs of maternal vascular 
malperfusion in the placenta
This is supported by the significant difference seen in maternal serum levels associated with 
placentas showing an increase in MTGC in the decidua when compared to placentas with normal 
decidual histology. MTGC are seen in normal placental development during implantation. The 
number of MTGC are however inversely proportional to gestation. Numbers are high during the first 
trimester but reduce as gestation advances. As the placenta continues to provide for the needs of 
the growing and developing fetus, the EVT need to continue their functions of invasion and 
remodelling of the spiral arteries in order to reduce the resistance of the maternal vessels. The 
MTGC are fused EVT that have lost the ability to invade. A higher number seen at term suggests poor 
invasion by the EVT. This in turn would give rise to lack of remodelling of the uterine blood vessels, 
which can affect blood flow to the fetus. We have seen how DLK1 has an effect on placental weight 
and volume, which indirectly suggests an influence on placental function. An increased number of 
MTGC in late gestation can result in poor Doppler flow studies as seen in IUGR. This was certainly the 
case in our participants with IUGR and low maternal DLK1 serum levels. It would be useful to analyse 
serum DLK1 levels in the first trimester at a point when interventions can be taken to improve 
vascularisation. Currently aspirin is commenced in high-risk pregnancies as dictated by previous 
101 
 
obstetric history and co existing medical conditions. The IUGR fetus needs early diagnosis and 
management in order to minimise neonatal and perinatal mortality. Presence of MTGC at term can 
be compared to serum DLK1 levels at this early gestation in order to assess the predictive value of 
DLK1 in abnormal invasion at this gestation. Our cohort underwent blood sampling at 12 weeks as 
part of the follow-up carried out by our obstetric collaborators. In the first instance these samples 
can be obtained and ELISA studies carried out for DLK1. A significant difference between the IUGR 
and AGA groups can for the first time provide an early marker for abnormal implantation.
5.7 Limitations of study
Gestation has been shown to influence DLK1 concentration. A small cohort such as the RLH cohort 
means that the influence of gestation, however small may limit experiments. Further work is 
warranted particularly prospective studies, as these allow for more accurate and focused data 
collection. A larger cohort may therefore reinforce some of my findings.  In addition, some of the 
immunohistochemistry studies may have more weight with a larger cohort and further allow us to 
associate pathology with DLK1 levels.
5.8 Proposed mechanism of action of DLK1 
A proposed mechanism of DLK1 action is seen below (Figure 22). Overall this work has shown 
important and novel associations between DLK1 and intrauterine growth. The prospective nature of 
our data collection allowing for serial measurements of parameters gives this work strength. Further 
work however needs to be carried out to understand the mode of action of this molecule. In 
particular, the identification of sequence or epigenetic variants may allow for genetic screening in 
cases where DLK1 levels are found to be low. If epigenetic variants are found, larger studies 
including pregnancies complicated by smoking, alcohol and other substance ingested during 
pregnancy can be reviewed to assess whether there is an effect on DLK1 expression at a genetic 
level in these cases.   
102 
 
Figure 25: Proposed mechanism for DLK1 mode of action  
Proposed mechanism of action of DLK1 in intrauterine growth. Flow diagram showing the proposed 
mechanism of action of DLK1 in influencing fetal growth either directly on the fetus or indirectly via effects on 
the placenta.  
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Chapter 6: Further studies informed by the current results 
6.1 Introduction 
The exact mechanism of action of DLK1 protein is not well understood. We have shown DLK1 
staining in the placenta specifically in fetal endothelial cells and trophoblast cells. It is however not 
clear whether DLK1 is synthesised by the placenta or the fetus, in human pregnancies. Given the 
staining pattern we have seen in the trophoblast group of cells however there may be an element of 
synthesis both within the placenta and the fetus. This is likely to change during gestation however 
and may also be under the control of various fetal/ placental signals. An understanding of the source 
of DLK1 will allow a better appreciation of the proposed mechanism of action, which can further 
provide a target for intervention or allow for closer and more accurate monitoring during pregnancy. 
In addition, some developmental studies to detect DLK1 staining and relate this to serum samples 
taken at the same time can further elucidate the function of this protein. Work on nutrient 
transporters within the placenta in addition to metabolic studies would be helpful in understanding 
the actions of DLK1 in the placenta. Below we describe proposed further work to support current 
findings.  
6.2 Are there genetic or epigenetic variants seen in cases of low DLK1 
levels? 
Given my initial results, it would be useful to assess whether the changes in DLK1 levels during 
gestation and with pathology were associated with changes in the genome. DLK1 primers were 
designed and optimised as described in chapter 2.  It was possible to optimise primers for 4 out of 
the 5 exons of DLK1 (Exon 2 – 5) (Figure 23). Fetal DNA was extracted from umbilical cords of our 
participants but good signals were only yielded on sequencing PCR products from exon 4 however. 
The experiment was abandoned due to time constraints but it would however be helpful to pursue 
this further with a view to designing robust primers for the experiments.   
Further work is required to assess the presence sequence variants in the DLK1 coding region that 
commonly associate with low maternal serum DLK1 and if the levels of DNA methylation at the 
imprinting control region or other well described regulatory regions correlate with alterations of 
DLK1 in maternal serum. Our group have extensive experience of epigenetic profiling within this 
region in the mouse, and robust assays for measuring methylation at the chromosome 14 imprinting 
control regions in the human have been published. These studies would provide an additional level 
of mechanistic information about variation in DLK1 dosage, as well as potentially identifying 
epigenetic/genetic markers for IUGR.  
104 
 
  
Figure 26: DLK1 PCR products for Exon 2 – 5  
Bands corresponding to the size of the primers seen with exon 2,3 4 and 5 respectively. Ladder is seen on the 
left with corresponding sizes.  
Differential expression of a number of imprinted genes including DLK1 has been shown in cases of 
IUGR102,104. Gene expression at the DLK1-DIO3 imprinting cluster is regulated at multiple levels. 
These regulatory mechanisms can take place both during transcription and post transcription. 
Transcription generates RNA strands ranging from long to short non-coding RNAs (ncRNA). These 
include microRNAs, piwi interacting RNAs, small nucleolar RNAs and long intergenic RNAs. 
MicroRNAS function as guide molecules in post transcriptional gene regulation by base pairing with 
target mRNAs, usually in the 3’ UTR167. Certain non-coding microRNAs have been identified to be 
perturbed in both human and animal studies167–170. The DLK1-DIO3 genomic region hosts one of the 
largest microRNA clusters in the genome171. Many of these microRNAs are differentially expressed in 
severe pathological processes and cancer168,172–175. The microRNAs can be studied by obtaining RNA 
from tissue samples from our cohort stored in RNA later. Further expression in this cluster can be 
regulated at the two DMRs as mentioned in chapter 1. Methylation studies to detect the presence of 
differential methylation in the DMRs between our two groups within our cohort may provide useful 
information. For both experiments, it would be useful to match cases and controls, rather than 
performing these experiments on the whole cohort. It would be useful to choose abnormal cases 
with low DLK1 levels and IUGR with a finding of MTGC clusters in the maternal decidua. Controls will 
be of matched gestation. Testing if there are sequence variants in the DLK1 coding region that 
commonly associate with low maternal serum DLK1 and if the levels of DNA methylation at the 
imprinting control region or other well described regulatory regions correlate with alterations of 
DLK1 in maternal serum would provide further information. These studies will provide an additional 
level of mechanistic information about variation in DLK1 dosage, as well as potentially identifying 
epigenetic/genetic markers for IUGR. 
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6.3 Which cell types/ compartments are involved in the synthesis of 
DLK1? 
Immunohistochemistry studies have shown DLK1 staining in the fetal endothelial cells and 
trophoblast layers. Positive staining in the trophoblast layer of cells appeared to include the CT, ST 
and EVT. When staining is looked at in more detail we see that the staining in the fetal endothelial 
cells is cytoplasmic and dot like. This appearance is suggestive of the peri-nuclear Golgi zone and 
would indicate an active DLK1 synthesis within these cell types. In the trophoblast cells DLK1 staining 
is also cytoplasmic but seen to be uniform. This may suggest an important regulatory function. In 
situ studies would be useful in clarifying sites of mRNA expression and comparing these with areas of 
localisation by immunohistochemistry studies. A midi prep is available allowing for construction of a 
DLK1 labelled probe, which can then be used to identify mRNA expression within placental cells.  
6.4 Which cells express DLK1 in early gestation and how does this 
change during pregnancy? 
I would be useful to carry out equally robust immunochemistry studies on early gestation placenta, 
in order to better understand events at these gestations. In situ studies on these placentas would be 
useful in ascertaining mRNA expression of DLK1 through gestation. It would be useful to obtain 
tissue from 18, 28 and 34 weeks gestation in addition to some earlier gestation tissue, in order to 
compare DLK1 expression to our already existing serial data collected from our cohort at these 
gestations.  
6.5 How does DLK1 carry out its function? 
DLK1 appears to have an important function in intrauterine growth. Whereas DLK1’s impact on 
tissue and organism development is substantial, the mechanism behind its underlying function is 
poorly understood. Clarifying the mode of action of this molecule would be valuable particularly if 
this molecule proves useful as a biomarker in pregnancy. DLK1 function is likely to be dependent on 
cell type. The effects in pregnancy as suggested by the results seen in chapter 3 and 4 are likely to be 
achieved through action on the placenta and also directly on fetal cells. The most characteristic 
placental cells are the trophoblasts. These cells have different phenotypes and as described earlier 
have roles in hormone secretion, nutrient transport in addition to maternal decidua invasion. In the 
first instance, co-localisation of DLK1 with nutrient transporters (e.g. GLUT1 and system A amino 
acid transporters) and in addition insulin, leptin and placental growth hormone may help elucidate a 
mode of action for DLK1 in intrauterine growth. This can be achieved by immunohistochemistry 
studies on placental histology slides. Secondly, stimulation studies can be carried out using human 
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placental explants, isolated primary human CT or cell lines such a choriocarcinoma derived BeWo 
(mimic in vivo functions of CT) or HTR8/SVneo (transformed EVT cell line)176. The respective cell lines 
can undergo treatment with varying concentrations of DLK1 (using the different isoforms including 
full length, soluble and intracellular forms), after which the amount of protein (western blots) and 
quantity (mRNA via RT-PCR) can be assessed. Further experiments can be carried out to assess the 
influence of DLK1 on the endocrine functions of the placenta. We know that the CT, ST and EVT 
secrete various placental hormones with important functions in fetal growth, maternal spiral artery 
remodelling and trophoblast cell invasion. Abnormalities in these processes can lead to IUGR. Cell 
lines can be treated with varying concentrations of DLK1 after which enzyme immunoassays can be 
used to measure production of the important placental hormones such as Leptin, the IGFs and 
Insulin. Furthermore, cells in both explant cultures and cell cultures from the HTR8/SVneo cell line 
can be used to assess a role for DLK1 in trophoblast invasion using cell invasion and migration 
assays176. 
These experiments can be further supported by maternal serum insulin, IGF1 and leptin levels in 
order to further access the influence of these hormones if any, on the function of DLK1. Further 
potential modes of action of DLK1 are supported by my immunohistochemistry findings. In Figure 23 
DLK1 staining is seen in the BM of the ST. In addition there is uniform cytoplasmic staining. Dot-like 
staining is seen in the fetal endothelial cells.  
DLK1 is highly homologous to NOTCH ligands and participates in multiple developmental processes 
in which also NOTCH receptors and ligands are known to play pivotal roles177. The five known 
canonical activating NOTCH ligands were previously thought to interact with their receptors via a 
DSL domain. Emerging evidence suggests however that non-canonical ligands such as DLK1 also 
exist178,179. These studies suggest that NOTCH is responsible for DLK1 function during development 
but DLK1 may also work through NOTCH – independent mechanisms depending on the tissue or cell 
type. They also suggest that DLK1 may interact with itself to produce effects. Once a proposed 
mechanism of action is arrived at from studies on cell cultures of both primary cells and cell lines as 
mentioned above, the signalling pathways thought to produce DLK1 effects can be interrogated 
further.
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Figure 27: DLK1 staining in term villi  
Dot-like staining is seen on the BM of the ST (black arrow) with additional uniform cytoplasmic staining of the 
ST. ST  - syncytiotrophoblast  
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Chapter 7: Conclusions 
 
I have shown that DLK1 has an important role to play in fetal growth. Emerging work particularly 
animal studies have confirmed this with more recent studies suggesting that the source of DLK1 in 
pregnancy is the fetus, at least in rodents as shown by Cleaton et al143. The influence on growth may 
be through DLK1’s effect on intrauterine nutrient supply and signalling. Rather than just be the 
effect of one protein, it is likely that the effects on growth are secondary to an interaction between 
DLK1 and IGF2, amongst other hormones. Further exploration of the association between DLK1 and 
autoimmunity is warranted particularly due to the identified link with type 1 DM83. There have been 
suggestions that there is an association between genomic imprinting and autoimmune disease, 
which may explain the role of DLK1 in this setting. Either way DLK1 is an important molecule that 
appears to have various roles and therefore further work is warranted to improve understanding of 
this multifaceted molecule. An understanding of its role particularly in utero may result in 
prevention or better management of intra uterine pathology that we know can have far reaching 
effects well into adult life. 
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APPENDIX 1 
Patient demographics 
Maternal 
age 
Maternal 
weight (kg) 
Ethnicity Gravidity/ 
Parity 
Height 
(m) 
BMI GA 
at 
birth 
Birth Birth 
weight length 
(grams) (cm) 
24 67 N.African G1, P0 1.53 28.6 40.71 3000  
29 62.2 Caucasian G1,P0 1.7 21.52 42.14 3680 51.5 
34 56 Chinese G1,P0 1.6 21.87 39.43 2610 42 
28 65 Caribbean G4, P1 1.63 24.46 41.29 3230 51 
29 59.9 Bengali G2,P1 1.54 25.26 39.14 2980  
28 72 Caucasian G3,P1 1.6 28.1 39.29 2420 44.8 
32 59 Caucasian G1,P0 1.66 21.41 39 3200  
34 64.2 Caucasian G1,P0 1.68 22.75 40.86 3640 49.5 
30 44.5 Caribbean G3,P1 1.54 18.76 39.29 2680 48.6 
20 64 Caribbean G1,P0 1.76 20.66 40 3220  
35 103 Caucasian G1,P0 1.57 41.79 40.14 3250 51 
30 76 Indian G1,P1 1.63 28.6 38.29 3040 50.4 
25 74.4 Bengali G2,P0 1.65 27.33 40.86 3000 50.5 
31 80.6 Pakistani G2,P1 1.55 33.55 39.29 3120 49.7 
37 71 Caucasian G1,P0 1.66 25.77 40.57 3280 50.02 
29 71 Bengali G3,P2 1.56 29.17 41.71 3120 52 
32 58.4 Chinese G3,P1 1.66 21.19 39.57 3515 51.9 
31 65.5 A. 
American 
G1,P0 1.68 23.21  26.86   950  
31 62 Indian G1,P0 1.57 25.15 39.14 3360 47.5 
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25 65 Caucasian G1,P0 1.67 23.31 41 3620 52.4 
33 52.4 Caucasian G1,P0 1.66 20.2 37 1860        
28 62 Bengali G4,P2 1.52 26.84 37.14 1720 44.5 
32 58 Chinese/ 
 
Caucasian 
G2,P1 1.65 21.3 39.9 3500 49 
24 73 Caucasian G1,P0 1.62 27.82 39.86 3500 49 
30 69 African G3,P2 1.68 24.45 39.29 3540 51.4 
25 76.4 Caucasian G1,P0 1.74 25.2 39.26 3040 52.3 
17 51.5 Bengali G1,P0 1.57 20.89 42 3640 51 
39 66 Phillipina G2,P1 1.56 27.12 41.14 3580 50.5 
24 52 N. Africa G1,P0 1.65 19.1 39 2900  
23 59 Bengali G2,P0 1.5 26.22 40.43 3425 51.8 
37 109 Bengali G2,P0 1.63 41.03   33.57   1340     40.5 
35 47.8 Malaysian G1,P0 1.57 19.39 38.43 2640 47.6 
26 65.8 Bengali G2,P0 1.54 27.74 39.71 3060 51.2 
 
Table showing patient demographics. IUGR patients are shown in bold italics.  
 
APPENDIX 2 
Antenatal parameters
Gestational age 
(weeks) 
AC (mm) FL (mm) BPD (mm)  DLK1 ng/l 
20.23 ±0.58 147.7 ±7.57 32.09±1.87 48.75±2.54 12.66±6.83 
27.95±0.75 227.4±10.31 51.89±2.47 72.89±2.98 43.17±21.35 
34.29±0.94 285.1±17.49 64.17±3.14 87.11±4.58 66.91±27.74 
37.86±1.21 324.2±14.25 70.85±3 92.84±3.73 87.08±51.39 
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Table showing antenatal parameters. Mean (±std dev). AC – abdominal circumference, FL – Femoral 
length, BPD – Bipareital Diameter
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APPENDIX 3 
Placental characteristics
 
Placental characteristic are show in the table above. Mean ± std deviation or N values are shown 
depending on parameter.  
Parameters Mean/ N 
Placental weight 426.6 ± 122.8 
Feto: placental ratio 7.64±2.36 
Placental length 189.3±64.26 
Placental width 152.8±21.95 
Placental depth 26.48±5.11 
Cord insertion 
Central: 
Peripheral: 
Marginal: 
 
N= 5 
N = 15 
N = 5 
No of vessels in cord 
2 vessels: 
3 vessels: 
 
1 
24 
Cord diameter 15.28±16.2 
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APPENDIX 4
Scatter showing individual participants and DLK1 levels during 
pregnancy
Post delivery samples are shown in red.  
0
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APPENDIX 5
Presentations carried out as a result of this work
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